This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, P. Y. Articles by Handelsman, D. J. Search for Related Content PubMed PubMed Citation Articles by Liu, P. Y. Articles by Handelsman, D. J.

Androgens and Cardiovascular Disease

ANZAC Research Institute (P.Y.L., D.J.H.), Department of Andrology (P.Y.L., D.J.H.), Concord Hospital; and Department of Medicine (A.K.D.), University of Sydney, Sydney, New South Wales 2139, Australia

Correspondence: Address all correspondence and requests for reprints to: Prof. D. J. Handelsman, ANZAC Research Institute, Concord R.G. Hospital, Building 51, Hospital Road, Sydney, New South Wales 2139, Australia. E-mail: djh{at}anzac.edu.au

	Abstract

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
Globally, cardiovascular disease will continue causing most human deaths for the foreseeable future. The consistent gender gap in life span of approximately 5.6 yr in all advanced economies must derive from gender differences in age-specific cardiovascular death rates, which rise steeply in parallel for both genders but 5–10 yr earlier in men. The lack of inflection point at modal age of menopause, contrasting with unequivocally estrogen-dependent biological markers like breast cancer or bone density, makes estrogen protection of premenopausal women an unlikely explanation. Limited human data suggest that testosterone exposure does not shorten life span in either gender, and oral estrogen treatment increases risk of cardiovascular death in men as it does in women. Alternatively, androgen exposure in early life (perinatal androgen imprinting) may predispose males to earlier onset of atherosclerosis. Following the recent reevaluation of the estrogen-protection orthodoxy, empirical research has flourished into the role of androgens in the progression of cardiovascular disease, highlighting the need to better understand androgen receptor (AR) coregulators, nongenomic androgen effects, tissue-specific metabolic activation of androgens, and androgen sensitivity. Novel therapeutic targets may arise from understanding how androgens enhance early plaque formation and cause vasodilatation via nongenomic androgen effects on vascular smooth muscle, and how tissue-specific variations in androgen effects are modulated by AR coregulators as well as metabolic activation of testosterone to amplify (via 5-reductase to form dihydrotestosterone acting on AR) or diversify (via aromatization to estradiol acting upon estrogen receptor /ß) the biological effects of testosterone on the vasculature. Observational studies show that blood testosterone concentrations are consistently lower among men with cardiovascular disease, suggesting a possible preventive role for testosterone therapy, which requires critical evaluation by further prospective studies. Short-term interventional studies show that testosterone produces a modest but consistent improvement in cardiac ischemia over placebo, comparable to the effects of existing antianginal drugs. By contrast, testosterone therapy has no beneficial effects in peripheral arterial disease but has not been evaluated in cerebrovascular disease. Erectile dysfunction is most frequently caused by pelvic arterial insufficiency due to atherosclerosis, and its sentinel relationship to generalized atherosclerosis is insufficiently appreciated. The commonality of risk factor patterns and mechanisms (including endothelial dysfunction) suggests that the efficacy of antiatherogenic therapy is an important challenge with the potential to enhance men’s motivation for prevention and treatment of cardiovascular diseases.

I. Introduction

II. Gender, Life Span, and Cardiovascular Disease

III. Newer Aspects of Androgen Action

A. Genomic regulation of androgen sensitivity

B. Nongenomic effects

C. Metabolic activation of testosterone

D. Derived measures of testosterone and SHBG

E. Fetal programming and perinatal androgen imprinting

IV. Vascular Biology

A. Gender

B. Androgen treatment

C. Genomic effects

D. Nongenomic effects

E. Vascular reactivity

V. Coronary Artery Disease

VI. Hypertension

VII. Cardiac Hypertrophy and Failure

VIII. Cerebrovascular Disease

IX. Peripheral Arterial Disease

X. Erectile Dysfunction

XI. Conclusion: the Present and Future

	I. Introduction

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
GLOBALLY, CARDIOVASCULAR DISEASE will remain the major cause of human deaths well into the 21st century (1). Medical progress in this field has followed identification of pathogenic factors as clues leading to novel mechanistic insights, prevention strategies, and therapeutic targets. This has created specific targets for prevention and/or treatment, including hyperlipidemia, diabetes, smoking, hypertension, clotting mechanisms, and vessel occlusion. Yet, the higher male risk of myocardial ischemia may be the oldest clue to the pathogenesis of atherosclerotic cardiovascular disease. The first known recognizable description of myocardial ischemia, written 2000 yr ago by Seneca (4 BC–65 AD), a Roman stoic philosopher (but not a physician) describing his own disease, recorded that "The attack is very short, and like a storm. It usually ends within an hour... . To have any other malady is to be sick, to have this is to be dying" (2). Since then, numerous reports eventually led to systematic clinical observations (2) that have recognized the higher male risk for at least two centuries (3). Cardiovascular disease shows a consistent male to female ratio of 2.2 (range, 1.2–4.5) among different populations despite wide variations in absolute rates (3).

Over recent decades, the gender disparity in cardiovascular disease has been interpreted primarily as reflecting estrogen-mediated protection against atherogenesis. Despite remaining unproven by prospective clinical trials, this dominant belief then shaped the direction of much mechanistic research leaving the plausible alternative, i.e., that androgens promote atherosclerosis, little studied. After the first prospective, placebo-controlled, randomized clinical trials (RCT) that showed no cardiovascular benefits of combined estrogen/progestin therapy in menopausal women (4, 5), fundamental rethinking has taken place on whether and how reproductive hormones influence cardiovascular disease, invigorating and reorientating basic and applied biomedical research. This interest is also sharpened by the widening use, misuse, and abuse of androgens in the community. The safety of wider androgen use needs careful scrutiny because even minor deleterious effects on cardiovascular disease, as the most frequent cause of death, are likely to outweigh even substantial perceived benefits from androgens in any medical, lay, or abusive context (6). This review aims to highlight newer findings as well as gaps and opportunities for research relevant to understanding the role of androgens in the male predisposition to earlier onset atherosclerosis as well as the safety of androgens as increasingly used in the community. The role of androgens in lipid metabolism, hemostasis, obesity, and insulin resistance is well reviewed elsewhere (7).

	II. Gender, Life Span, and Cardiovascular Disease

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
A strikingly consistent feature of human populations is the gender gap in life span (8, 9). At birth, life expectancy is consistently shorter for men than women across virtually all populations. In 186 of 191 (97%) United Nations member countries, men have shorter life expectancy by an average of 5.6 yr in those countries above a minimal level [Gross Domestic Product (GDP) in U.S. dollars, $3000 per capita] of economic development (Fig. 1). The gender gap in life span has not narrowed over the last century, and it seems unlikely to diminish without effective targeting. Because cardiovascular disease is the leading cause of human deaths, gender differences in its onset and severity must make an important contribution to the gender gap in life span. This contrasts with causes of death that may be more frequent among men (e.g., trauma, infectious disease) but are quantitatively minor at a population level (10).

View larger version (13K): [in this window] [in a new window]   Figure 1. Gender gap in life expectancy. Plot of gender gap in life expectancy, expressed as life expectancy at birth for women minus that for men (y-axis) against GDP per capita (in thousands of 1985 U.S. dollars) in 88 United Nations member countries for which both variables were available. Data obtained from WHO World Health Reports for 2002 (for life expectancies at birth) and 1999 (latest estimates of GDP). Note that above a threshold of approximately $3000 GDP per capita, gender difference is consistent at a mean of 5.6 yr across a wide range of economic development.

Hormonal effects are the most tractable for practical therapeutics, given the plethora of reproductive steroids available. In recent decades, clinical practice and basic mechanistic studies focused almost exclusively on the estrogen protection hypothesis—that cardiovascular disease progression was slowed by estrogenic protection in premenopausal women, a protection lost after menopause. Despite lacking proof by well-controlled prospective studies, the estrogen protection hypothesis became familiar, almost axiomatic. This status was supported by observational case-control studies finding that menopausal women using estrogens had less cardiovascular disease. As established in clinical practice, this dominant hypothesis determined that basic vascular biology studies would focus largely on mechanisms of estrogenic protection from atherosclerosis. In retrospect, selective recruiting of healthier and wealthier women, who are more likely to afford and prefer hormone replacement therapy, into case-control studies gave ultimately false reassurance. This limitation of observational research in eradicating or accounting fully for bias and confounding (17) reemphasizes a division of labor in clinical research, with observational studies being economic and efficient for hypothesis generation but well-controlled interventional studies remaining pivotal, the gold standard, for hypothesis testing. It is salient that, despite decades of clinical practice and supportive observational research, the Heart and Estrogen/Progestin Replacement Study (4) and Women’s Health Initiative (5) studies were the first placebo-controlled RCTs to test the estrogen protection hypothesis.

In fact, the dominance of the estrogen protection hypothesis overlooked contemporaneous evidence (18, 19, 20), consistently failing to confirm any break-point in female cardiovascular risk at the expected age of menopause, a key prediction of this hypothesis (21, 22). This contrasts with other definitely estrogen-dependent biological end-points, such as breast cancer and bone density (Fig. 2), that show inflection points in population data at the modal age of menopause. Moreover, cardiovascular death rate curves appear parallel for men and women, apart from an offset of approximately 5 yr in women. This is most consistent with the same disease process in both genders, but with an early head start in men rather than a continuous exposure to a greater risk in men that would tend to produce diverging lines. Such a head start might reflect biological processes that occur early in life (e.g., perinatal androgen surge in boys) or, perhaps, early in the pathogenesis of atherosclerosis. Furthermore, the estrogen protection hypothesis when applied to men, predicting that estrogen treatment reduces cardiovascular disease deaths, was conclusively refuted by the mid-1970s with two major well-controlled studies showing estrogen treatment of men caused excess cardiovascular deaths. Between 1966 and 1969, the Coronary Drug Project recruited 8341 men aged 30–64 yr from 53 centers who were randomized into various treatments or placebo for secondary prevention of myocardial infarction. Both high (5.0 mg) and low (2.5 mg) dose conjugated equine estrogen treatment arms were discontinued prematurely due to excess thromboembolism (23). In the early 1960s, the Veterans Administration Cooperative Urological Research Group recruited 2052 men with prostate cancer from 14 centers (24). Those randomized to treatment with 5.0 mg/d diethylstilbestrol had excess cardiovascular deaths compared with placebo regardless of stage. The excess mortality was a direct estrogen effect, rather than indirectly due to estrogen-induced castration, because the orchidectomy-alone treatment arm did not experience excess mortality. A caveat is that both studies used oral estrogens, which inevitably causes hepatic estrogen overdosage due to first-pass effects, further exaggerated by the high doses used. Because the oral route of administration is a major factor contributing to thromboembolic risk among users of estrogen for contraception or menopause, it is tempting to speculate that nonoral delivery of synthetic estrogen partial agonists ("selective estrogen receptor modulators") might have better outcomes.

View larger version (26K): [in this window] [in a new window]   Figure 2. Cardiovascular death rates in women do not exhibit an inflection point at expected modal age of menopause, unlike other unquestionably estrogen-dependent processes such as breast cancer and bone density that show a clear break-point at the expected age of menopause. Cardiovascular death rates in women and men in the United Kingdom, redrawn from the work of Tunstall-Pedoe (21 ) and plotted on a linear scale (top left panel) or log scale (top right panel), show no inflection point at modal age of menopause and a highly congruent curve displaced (delayed) by approximately 5 yr in women. By contrast, death rates from breast cancer (bottom left panel) and bone density (bottom right panel) show a clear inflection point around the end of the fifth decade of life. Breast cancer and cardiovascular death rates from 1962 U.S. women, redrawn from the work of Tracy (18 ). Bone density data from the National Health and Nutrition Examination Survey III (1988–94) is based on 6181 white U.S. men and women. [Top panels reproduced with permission from The Lancet (21 ).]

The natural history of complete androgen resistance due to a mutated, nonfunctional AR (36), combining male genetic sex with female phenotype, would provide a decisive test of whether life span or cardiovascular mortality followed male or female patterns. However, standard medical care of this rare disorder abrogates its natural history, making it unlikely that such data will ever be available. Alternatively, female-to-male (F2M) transgender, in which genetic females receive male testosterone doses, provides useful information. The only available follow-up study reported no excess cardiovascular disease among 293 F2M transsexuals during 2418 patient-years of exposure, compared with the general population (37). Longer and larger follow-up studies of such populations would be of considerable interest. Lower but more sustained exposure to androgen excess in women with polycystic ovary syndrome is also associated with no excess of cardiovascular disease (38) or mortality (39), despite increases in cardiovascular risk factors (40, 41), endometrial (but not breast) cancer (42), and more extensive atherosclerosis at coronary angiography (43). Because it is highly unlikely that these studies could have overlooked the greatly increased (7.4-fold) risk predicted by risk factor modeling (44), this striking discrepancy raises the possibility that androgens may have beneficial as well as detrimental effects on atherogenesis in women. If perinatal androgen imprinting is important in triggering male-pattern cardiovascular risk, both F2M transgender and women with polycystic ovary syndrome would lack this exposure, which might explain their relative freedom from cardiovascular complications.

The cardiovascular effects of androgen abuse have been extensively reviewed (7, 45, 46, 47). Adverse cardiovascular effects including myocardial infarction, hypertension, arrhythmia, cardiac failure, pulmonary embolism, stroke, and sudden death have been associated with androgen abuse, based on the temporal relationship to usage. Virtually all are single case reports of events that can occur in the absence of androgen usage and, in some, underlying medical disorders contribute to the risks (48). Without knowing the denominator of community exposure, the actual individual risks of such adverse effects compared with the general community are not clear (49). Given the highly prevalent and sustained usage among elite power athletes and bodybuilders for the last four decades, it is conceivable that the actual risks may not prove high. The East German national sports doping program involved more than 2000 elite athletes annually being treated with high-dose synthetic androgens. Regular medical monitoring recorded no cardiovascular complications, whereas liver disease and many other complications were regularly recorded (50). The longevity of former elite athletes who may have abused androgens may also shed light on the cardiovascular risks of androgen abuse. In a study of 2613 Finnish former elite athletes and age- and locale-matched conscripts, endurance and team athletes had lower cardiovascular mortality and longer lives than the general population (51), consistent with findings among Italian track and field athletes (52) and Dutch distance skaters (53), whereas those in power sports had less extended lives (51). Finnish power lifters among whom androgen abuse was suspected but not verified had 4.6-fold higher overall mortality, although life expectancy and cardiovascular mortality were the same as community controls (54). Further studies are needed to clarify the actual long-term cardiovascular and other risks associated with androgen abuse in former athletes.

In summary, the gender gap in life span is consistent in all but the poorest countries. The best available data suggest that adult male androgen exposure does not shorten men’s life span, but oral estrogen treatment has deleterious cardiovascular effects in men, as it does in women. How much of this harm is due to the oral route of administration or the use of synthetic estrogens is not clear. The risk of harmful cardiovascular effects due to high-dose androgen exposure from androgen abuse needs further clarification. If the gender differences in cardiovascular disease, which must contribute to the gender gap in life span, are due to hormonal effects, they presumably operate early in the pathogenesis of atherosclerosis.

	III. Newer Aspects of Androgen Action

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
Expanding knowledge of androgen physiology has shed light on new mechanisms that may be crucial to better understanding androgen action on the vasculature for both basic and clinical research.

A. Genomic regulation of androgen sensitivity
The classical pathway of androgen action (Fig. 3) involves steroid binding to the AR, a ligand-activated transcription factor, and single copy member of the nuclear receptor superfamily, acting on the genome (36). The genomic action of AR is modulated by a large variety of coregulators, which are proteins that fine-tune target gene expression by enhancing (coactivator) or restraining (corepressor) transcription (55). Although testosterone circulates throughout the body, the factors responsible for variation in tissue androgen sensitivity remain to be further clarified. Intensity of expression of the single human AR (56) partly defines androgen sensitivity, but AR is almost ubiquitously expressed to some degree in tissues. Further biological determinants of tissue androgen sensitivity, including the functional AR polymorphisms as well as tissue distribution and regulation of AR coregulators, androgen metabolic enzymes, and nongenomic mechanisms, remain to be better defined so that their net integrated effects can be understood better.

View larger version (39K): [in this window] [in a new window]   Figure 3. Nongenomic and genomic androgen mechanisms. Left, Nongenomic effects of testosterone, which are triggered by binding to a still uncharacterized (nonclassical) membrane receptor. This activates second messengers including calcium and protein kinases, which produce typically rapid responses. Genomic effects are depicted in the middle and on the right. Testosterone (or other aromatizable synthetic androgens) crosses the cell membrane to be converted to estradiol (or the aromatic synthetic analog) by aromatase, which then binds to and activates ER or ERß. Right, DHT (or other nonaromatizable androgens) enters the cell to bind and activate the AR. Ligand-bound ER or AR dissociate their heat-shock protein (HSP), undergo conformational changes, dimerize, and translocate into the nucleus where they bind to specific sites known as estrogen response elements (ERE) or androgen response elements (ARE) located within the DNA of target nuclear genes to produce long-term genomic effects of testosterone.

Androgen sensitivity could be modulated by a functional polymorphism of AR that influences the strength of the genomic signal transduced from its interaction with an androgen as a bound ligand. One such functional AR polymorphism is the exon 1 triplet repeat CAG (polyglutamine) whereby the repeat length is inversely correlated with androgen sensitivity. Within the normal population, shorter repeat lengths are associated with higher risk of prostate cancer (60), whereas longer repeats are associated with reduced androgen effects on lipids and vascular reactivity (61) as well as bone (62) and sperm production (63) within the normal male population. Pathological extension (>40 repeats) causes a motor neuron disease (Kennedy’s syndrome, spinal muscular bulbar atrophy) with associated androgen insensitivity (64). Whether such fine-tuning of androgen responsiveness influences ultimate cardiovascular outcomes remains to be studied further. Further analysis of this and similar functional polymorphisms of androgen metabolizing enzymes (5-reductase, aromatase, CYP3A4; Ref. 65) may shed new light on androgen action on the cardiovascular system.

The development of the first nonsteroidal androgens (66, 67) has promise in exploiting tissue-specific differences in androgen sensitivity (68). Whether such tissue-specific partial androgen agonists (selective AR modulators), which are structurally nonaromatizable and functionally dihydrotestosterone (DHT) analogs, would have useful roles in vascular therapeutics mediated via AR remains to be clarified. Pharmacological targeting of nongenomic androgenic vasodilator mechanisms in vascular smooth muscle seems promising, in contrast to endothelial and vessel wall mechanisms that involve aromatization.

B. Nongenomic effects
There is now considerable evidence for rapid, nongenomic effects of steroids (Fig. 3), including androgens (69). Nongenomic steroid action is distinguished from genomic effects by 1) rapid onset (seconds to minutes) that is faster than genomic mechanisms, 2) insensitivity to inhibition of RNA and protein synthesis, 3) effects produced by steroids unable to access the nucleus (either covalently linked to membrane impermeable macromolecules or in cells lacking a nucleus), and 4) not usually blocked by classical antagonists due to different steroidal specificity from classical cognate nuclear receptors. As for other steroids, nongenomic androgen effects characteristically involve the rapid induction of conventional second messenger signal transduction cascades, including increases in cytosolic calcium and activation of protein kinase A, protein kinase C, and MAPK, leading to diverse cellular effects including smooth muscle relaxation, neuromuscular and junctional signal transmission and neuronal plasticity (70). In addition, nontranscriptional mechanisms have also been reported (71). Most nongenomic effects involve a membrane receptor, and putative binding sites are described for all major classes of steroids (72), including androgens (70). In mammals, only a membrane receptor for progesterone has been cloned (73, 74), but functional characterization is lacking. A membrane progestin receptor cloned from fish ovary features a heptahelical transmembrane structure typical of G protein-coupled receptors, and the recombinant protein exhibits high-affinity binding of progesterone with activation of postreceptor signal transduction pathways (75). No membrane AR has been characterized, but preliminary evidence of a low-affinity microsomal membrane binding site for alkylated androgens (76) and an endothelial cell plasma membrane dehydroepiandrostendione (DHEA) binding site (77) still require functional proof of specific receptor status. A plasma membrane SHBG receptor capable of modulating androgen action at plasma membranes and initiating intracellular cAMP signaling has been described in humans (78). The SHBG receptor remains to be fully characterized, and it is not clear whether it has any physiological role in species like rodents that lack circulating SHBG.

C. Metabolic activation of testosterone
A key issue in the biological effects of testosterone is its conversion to bioactive metabolites (Fig. 4). Although only a small fraction (<5%) of testosterone output undergoes such transformation usually in local tissues, conversion both amplifies and diversifies testosterone action. Conversion to its 5-reduced metabolite, DHT, by either type 1 or type 2 5reductase amplifies testosterone action because DHT has higher molar potency due to its more avid binding affinity and slower dissociation rate from the AR (79). In the prostate, feed-forward induction by DHT of type 2 5-reductase (80) results in virtually all testosterone entering the prostate being converted to DHT, thereby greatly enhancing local AR-mediated effects. Type 1 and type 2 5-reductase has been identified in vascular tissues based on immunoreactivity (81, 82) and enzymatic activity (83, 84, 85), but the biological consequences of androgen amplification in vessel walls remain to be clarified (84, 86, 87). Furthermore, conversion of testosterone to estradiol by the enzyme aromatase (CYP19) diversifies androgen action by activating estrogen receptors (ER). Aromatase gene expression (88, 89, 90, 91), protein (90, 91, 92), and enzymatic activity (93) have been detected in vascular tissues, including human coronary arteries (92) particularly in endothelium and smooth muscle. A more complete picture of gender differences and sex hormone regulation of aromatase and 5-reductase activity in vascular tissues is needed.

View larger version (35K): [in this window] [in a new window]   Figure 4. Pathways of testosterone action. In men, most (>95%) testosterone is produced under LH stimulation through its specific receptor, a heptahelical G protein-coupled receptor located on the surface membrane of the steroidogenic Leydig cells. The daily production of testosterone (5–7 mg) is disposed along one of four major pathways. The direct pathway of testosterone action is characteristic of skeletal muscle in which testosterone itself binds to and activates the AR. In such tissues there is little metabolism of testosterone to biologically active metabolites. The amplification pathway is characteristic of the prostate and hair follicle in which testosterone is converted by the type 2 5-reductase enzyme into the more potent androgen, DHT. This pathway produces local tissue-based enhancement of androgen action in specific tissues according to where this pathway is operative. The local amplification mechanism was the basis for development of prostate-selective inhibitors of androgen action via 5-reductase inhibition, the forerunner being finasteride. The diversification pathway of testosterone action allows testosterone to modulate its biological effects via estrogenic effects that often differ from AR-mediated effects. The diversification pathway, characteristic of bone and brain, involves the conversion of testosterone to estradiol by the enzyme aromatase, which then interacts with ER and/or ERß. Finally, the inactivation pathway occurs mainly in the liver, with oxidation and conjugation to biologically inactive metabolites that are excreted by the liver into the bile and by the kidney into the urine.

Despite lacking theoretical validity, such derived testosterone measures might still be useful empirically if they provided prediction of, or correlation with, independent biological androgen effects that were superior to those of standard testosterone measurements. Such empirical validation, however, is conspicuously lacking. Some derived testosterone measures clearly lack face validity. For example, among derived measures purporting to estimate free testosterone, both the free androgen (or testosterone) index calculation (111) and the free testosterone analog assays (112, 113, 114) are well-known to be invalid in men. Other measures such as equilibrium dialysis to estimate the free fraction or the bioavailable (corresponding to free plus loosely albumin-bound fractions) may be technically reproducible (95, 96), but there is no evidence that they provide significantly superior or additional biological information to the measurement of total testosterone as judged by independent biological effects. In summary, derived testosterone measures lack theoretical or empirical validity, add little or no explanatory power to clinical or physiological research beyond measurement of total testosterone, and should be used, if at all, only with concomitant independent empirical validation of those measures. Further studies of the biological role of SHBG in modulating androgen action are needed.

E. Fetal programming and perinatal androgen imprinting
The role of early life environmental exposures on late life cardiovascular disease has recently been recognized. Barker (115, 116) has compiled evidence from a wide variety of sources implicating prenatal environmental programming as a major determinant of susceptibility to diseases of later life, notably cardiovascular disease (115) and type 2 diabetes (116), the latter termed the thrifty phenotype hypothesis. He proposes that fetal adaptation to intrauterine malnutrition, to prioritize protection of vital organs, conditions preferred metabolic pathways in developing organ systems (developmental plasticity). The perpetuation of such adaptations into postnatal life may foster mechanisms that are deleterious in adult life. The precise mechanisms leading to cardiovascular disease remain to be elucidated, but accelerated early growth following low birth weight is characteristic (117), especially in boys (118). Neonatal androgen imprinting determines the sexually dimorphic mature blood pressure patterns of SHR rats (119) and susceptibility to diet-induced hypertension (119). This may be an important clue, when considered in conjunction with the natural history of gender differences in cardiovascular mortality, that points to atherogenesis having similar progression in men and women but with men having a head start at some undefined early stage in pathogenesis. A key event in early male life is the perinatal androgen surge when blood testosterone concentrations reach adult levels for months. This epoch is critical for hormonal imprinting of brain (120), prostate (121, 122, 123), and probably other androgen-sensitive tissues, perhaps including vascular tissues. An informative clinical model to test the effects of perinatal androgen exposure is congenital adrenal hyperplasia. Women with 21-hydroxylase deficiency would usually experience marked androgen excess until effective treatment is instituted. This early life androgen excess is known to influence gender identity and role (124), but effects on life span and cardiovascular disease are not known. Interestingly, castration of inbred rats at birth prolongs life span, whereas castration at weaning or maturity has no effect (35). More specific examination of gender in relation to fetal environmental programming and related perinatal events, such as the androgen surge and hormonal imprinting, may be informative.

	IV. Vascular Biology

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
A. Gender
Gender differences are characteristic of animal models of atherosclerosis. Males develop earlier and more extensive atherosclerotic plaques independent of lipid levels in diet-induced models in the nonhuman primate (125) and in rabbits with (126) and without (127) intimal injury. Gender differences are also observed in the mouse atherosclerosis models involving apolipoprotein E (ApoE; Ref. 128) and low-density lipoprotein (LDL) receptor (129) deficiency as well as in the modulating influences on these models of hypertension (130), P-selectin deficiency (131), and peroxisome proliferator activator receptor agonist (132). Gender differences are reversed, with females developing diet-induced atherosclerotic plaques faster than males in certain mouse models such as ApoE-deficient mice (128, 133) and inbred mouse strains (134), although exogenous testosterone accelerates atherosclerosis in these models (133, 135). Maternal hypercholesterolemia in pregnant LDL receptor-deficient mice enhances atherosclerosis susceptibility of their male progeny, providing a mechanism for prenatal determination of susceptibility to cardiovascular disease (136). Mouse genetic susceptibility to atherosclerosis (137) or postinjury restenosis (138) varies between strains, with distinct susceptibility genes for each model (139). Although gender influences the relatively rapid vascular remodeling of postinjury restenosis in humans (140), the impact of gender on experimental restenosis models remains to be clarified.

B. Androgen treatment
Testosterone treatment consistently inhibits atherosclerosis in castrate, cholesterol-fed male rabbits (141, 142, 143). The most detailed study showed that castration of male rabbits increased, whereas both testosterone and DHEA treatment inhibited, aortic atherosclerosis. The higher testosterone concentrations produced by an injectable testosterone ester provided significantly better protection than an oral testosterone ester or DHEA. Testosterone effects were not explained by lipid mechanisms, whereas aortic ER (but not AR) content was down-regulated in parallel with atheroprotective effects. This suggestion of the importance of aromatization within the vessel wall for atheroprotection has been supported by observations that treatment with DHEA (readily aromatized) inhibits atherosclerosis in intact, cholesterol-fed rabbits (144, 145, 146), whereas a synthetic nonaromatizable androgen (stanozolol) had no protective effect (147). Similarly, in LDL receptor-deficient male mice, an aromatase inhibitor (anastrozole) blocked the atheroprotective effect of both endogenous and exogenous testosterone (91).

In female animals, however, proatherogenic effects of androgens are reported. Treatment of ovariectomized nonhuman primates for 1–2 yr with nandrolone decanoate (148) or 8 months with testosterone (149) increased coronary artery atherosclerotic plaque size compared with treatment controls and lower level androgen exposure (androstenedione plus estrone). The enhancement of atherogenesis was not explained by lipid changes or by the limited aromatizability of nandrolone. However, androgens also enlarged coronary diameter (148) and enhanced endothelium-dependent acetylcholine vasodilator responses (149), consistent with vasodilator effects of androgens.

In ApoE-deficient male mice, atherosclerotic plaque size is decreased by estradiol treatment of intact (150) or orchidectomized (151, 152) males. However, reported effects of testosterone are conflicting. A study using a GnRH antagonist (Cetrorelix) to deplete endogenous testosterone found that castration reduces, and testosterone treatment increases, atherosclerosis (133), whereas another study reported that orchidectomy had no effect and testosterone treatment reduces atherosclerosis (152). In LDL receptor-deficient male mice, orchidectomy increases, whereas testosterone or estradiol treatment reduces, atherosclerosis, and an aromatase inhibitor (anastrozole) blocks the atheroprotective effects of endogenous and exogenous testosterone (91). The speculation that these differences are due to extragonadal LH effects (133) lacks basis because no vascular effects of LH outside the reproductive tract have been established (153). Overall, animal models do not yet provide a fully coherent picture, but most evidence supports testosterone having an atheroprotective effect requiring aromatization in males, whereas in females androgens are proatherogenic. The role of 5-reduction in these testosterone effects has not been reported. Further studies using pharmacological probes (nonaromatizable androgens, blockers of androgen metabolism) and genetic mouse models to dissect components of testosterone action on the vasculature will be of continuing interest.

C. Genomic effects
AR is expressed in all cells of the vasculature, including endothelial cells, smooth muscle cells, myocardial fibers, macrophages, and platelets (Fig. 5). In earlier studies, myocardial (154) and aortic (155, 156, 157, 158, 159) AR content was similar in male and female rats (155, 156, 159), rabbits (158), and nonhuman primates (154, 157). However, males showed more nuclear localization, consistent with greater AR activation by endogenous testosterone (154, 155, 156, 157). Recent studies using more sensitive detection methods find consistent gender differences in vascular tissue AR content. Higher AR expression in males is reported for rat vascular smooth muscle (160), human macrophages from peripheral blood (161) or synovium (162), and mesenteric artery and endothelial cells (163). Hormonal regulation of AR protein levels in nonreproductive tissues including the vasculature is not well defined. Ligand binding initially stabilizes AR protein, but prolonged exposure leads to down-regulation (164). Male-specific expression of AR, such as in macrophages and smooth muscle cells, implies long-term AR protein up-regulation with prolonged exposure to endogenous male testosterone concentrations. Short-term exposure of rabbit arterial neointimal plaque to testosterone increased AR mRNA while inhibiting plaque development in culture (165).

View larger version (48K): [in this window] [in a new window]   Figure 5. Sites of androgen action on the vasculature, including sites where androgens have been shown to interact with the vessel wall and bloodstream components to initiate early stages of atherosclerosis, to propagate and enlarge the lesions, and to modify the late stage of plaque rupture.

Apoptotic damage of vascular endothelial cells is an important cellular mechanism in atherogenesis, leading to increased platelet adhesiveness and thus increased tendency for thrombus formation (173). Testosterone enhances endothelial cell apoptosis provoked by serum deprivation (as an in vitro model of arterial wall damage; Ref. 174). This testosterone effect is blocked by flutamide but is not replicated by DHEA or estradiol, indicating involvement of AR but not aromatization. Any role of 5-reduction has not been reported.

In the intact arterial wall, smooth muscle cells regulate the arterial tone and produce the extracellular matrix. Proliferation and migration of smooth muscle cells are important steps in the formation of neointima and stenoses. Testosterone and DHT treatment stimulate proliferation of rat vascular smooth muscle cells (84), whereas estradiol inhibits their proliferation and migration (175, 176). Consequently, postinjury neointimal plaque size is larger in males than females and increases after ovariectomy (but not orchidectomy) with restoration of intact female levels by estradiol replacement (177).

Macrophages play a key role in atherosclerosis by migrating into the vessel wall where they internalize large amounts of exogenous lipids by various unregulated scavenger receptors and phagocytosis. Lipid accumulation transforms macrophages into foam cells, forming the fatty streaks characteristic of early atherosclerosis. Experimentally, androgens enhance foam cell formation because lipid loading of male (but not female) macrophages is increased by DHT treatment, an effect blocked by flutamide consistent with an AR-dependent mechanism (161). Conversely, testosterone also enhances reverse cholesterol transport, which might retard development of fatty streaks. Testosterone at a physiological concentration increases expression of the scavenger receptor-B1 at mRNA and protein levels in human hepatocytes and monocyte-derived macrophages (178). The functional consequences of increased scavenger receptor-B1 were observed as testosterone-dependent enhanced transfer of cholesterol esters from monocyte-derived macrophages to high-density lipoprotein-3 during in vitro culture (178). Whether the testosterone effect required the AR or aromatization was not reported, but because estrogens reduce scavenger receptor B1 in nonsteroidogenic tissues (179), aromatization is not required. Any role of 5-reduction has not been reported. Testosterone treatment of murine macrophages inhibits nitrite release via inhibition of the inducible nitric oxide (NO) synthase (NOS) enzyme, although the underlying mechanism remains unknown (180). This inhibition of inducible NOS could increase platelet aggregation and thrombosis risk associated with androgen treatment by eliminating the antiaggregatory effects of NO.

D. Nongenomic effects
Among vascular cells, nongenomic effects of testosterone (Fig. 5) are described for macrophages (181, 182), endothelial cells (163, 183), and vascular smooth muscle. Macrophage cell lines (IC-21, RAW264.7) that do not express the nuclear AR show rapid and repeated increased cytosolic calcium responses to testosterone, DHT, and testosterone rendered membrane-impermeable by conjugation to BSA (T-BSA) but not to inactive androgens (5ß-DHT, 1-DHT) (181, 182). Testosterone effects were not blocked by classical antiandrogens (cyproterone, flutamide) or antiestrogens (raloxifene, tamoxifen, ICI182, 780) excluding the involvement of AR and aromatization, but the role of 5-reduction remains unclear. T-BSA was bound to plasma membranes and internalized by an energy- and cytoskeleton-dependent process. Based on blocker experiments, the calcium response originated from primarily internal stores coupled to phospholipase C via a G protein-coupled receptor (184). In RAW264.7, murine macrophages stably transfected with c-fos promoter (RAW-fos13), the functional effects of nongenomic testosterone signaling were illustrated by testosterone attenuation of lipopolysaccharide-activated c-fos promoter activity, p38MAPK, and NO production (182). In human endothelial cells, testosterone, T-BSA, and DHT all stimulate increased cytosolic calcium via membrane influx that was abolished by removing extracellular calcium or blocking membrane calcium channels but not by blockade of intracellular calcium stores (163). By contrast, in cultured rat, aortic endothelial cells testosterone inhibited bradykinin-induced increases in intracellular calcium but had no effect itself (183).

Testosterone-induced vasodilatation, first reported by Waldman in 1945 (185), is well established with in vitro vasodepressor effects reported in precontracted arteries of the rat (13, 186, 187, 188, 189, 190), mice (191), rabbit (192), pig (193, 194), guinea pig (195), ferret (196), and dog (197). These effects involve primarily the vascular smooth muscle without requiring the presence of endothelium, although an endothelial contribution is apparent in some studies (186, 197). Testosterone acts via a nongenomic mechanism because the responses are rapid; present in tfm rats with mutated, nonfunctional AR (186, 191, 198); reproduced by testosterone conjugated to membrane-impermeable macromolecules (189, 199, 200); and not blocked by inhibitors of DNA and protein synthesis (199, 201), classical AR antagonists (190, 199, 201, 202), aromatase inhibition (190, 192, 203), or ER blockers (197, 203). The mechanisms involved include endothelium-derived NO (where endothelium is involved) and, more regularly, blockade of membrane calcium influx via voltage-operated calcium channels (191, 204) and potassium efflux involving voltage-operated (13, 189) and BK_Ca (194) potassium channels (190) in vascular smooth muscle, including in humans (205). The steroidal selectivity of the putative membrane receptor involved in testosterone-induced vasodilation is unusual, with classical antiandrogens (cyproterone, flutamide) ineffective, whereas 5ß-androstanes (androsterone, etiocholanolone, 5ß-DHT) are more potent vasodilators than 5-androstanes (5-DHT, 3-diol), which is the reverse of their potency at the AR. Neither 3 nor 17 conjugation impairs vasodilatory activity (200). Testosterone induces vasodilatation in all arterial beds studied, comprising coronary, mesenteric, iliac, renal, and femoral (206), although sensitivity varies between them (192, 197, 206, 207, 208) and is reduced by aging (209).

The consistent requirement for high (micromolar) concentrations of testosterone for vasodilatory responses raises questions about the physiological nature of these responses. Few studies are reported at lower testosterone doses, but a recent in vivo study of pigs reported widespread arterial vasodilatory responses using testosterone infusions calculated to produce concentrations of approximately 1 µg/liter (206). At similar physiological concentrations of testosterone, however, vasoconstrictor responses have been observed (199, 201), including one study in which the higher, supraphysiological testosterone concentrations produced vasodilatation (201). Vasoconstrictor responses have long been known in tissues obtained from androgen-treated animals (195, 210, 211, 212, 213), but the effective tissue androgen concentrations involved are not clear. Further study of physiological testosterone concentrations would be of considerable interest.

E. Vascular reactivity
The vascular endothelium, a single cell layer separating blood and vascular smooth muscle, regulates vessel tone through release of vasoactive factors such as NO, endothelins, and prostanoids (214). As a cellular plane, it forms the surface on which blood cells, vessel wall growth, and adhesive factors interact to form the nidus of atherogenic lesion. The pivotal significance of endothelial NO release causing vasodilatation has facilitated the development of endothelial function tests. These tests are based on comparing the vascular effects of stimuli that cause endothelial NO release (endothelium-dependent stimuli) with endothelium-independent stimuli that deliver NO directly to vascular smooth muscle, bypassing the endothelium. The difference then represents the effect of endothelial-mediated NO release and vasodilatation. During coronary angiography, for example, acetylcholine represents an endothelium-dependent stimulus to be compared with nitrates as an endothelium-independent stimulus (215). The development of a noninvasive test [flow-mediated dilatation (FMD)] for arterial endothelial function (216) has allowed wider investigation of endothelial function, whereas biochemical tests of endothelium-derived markers remain of uncertain validity (214). FMD is estimated by measuring brachial artery diameter with ultrasound before and after reactive hyperemia (where shear stress causes endothelial NO release) and administration of sublingual glyceryl trinitrate (where drug release of NO is an endothelium-independent stimulus). Impaired FMD is a feature of early atherosclerosis, corresponding closely with extent of coronary heart disease (217), but it is also influenced by other variables that must be controlled for studies of FMD (214).

FMD studies provide insight into androgen effects on the human vasculature (Table 1). FMD is similar in men and age-matched women (218, 219) except for higher values during the estrogen-dominated follicular and luteal phases of the menstrual cycle (218). FMD declines with age in both men and women, although the decline starts earlier in men (220). Both endogenous and exogenous testosterone impair vascular reactivity in men. Vascular reactivity is enhanced by castration in older men with advanced prostate cancer compared with age-matched and cancer controls (221). In a large well-controlled study of 36 newly diagnosed, nonsmoking hypogonadal men, androgen deficiency was associated with markedly increased FMD compared with age-matched eugonadal controls (222). Testosterone replacement therapy reduces FMD (214, 222), although to levels lower than age-matched eugonadal controls (222), presumably reflecting limitations of the testosterone delivery system compared with endogenous production. A study of non-androgen-deficient men with coronary artery disease reported that FMD, but not nitrate-induced dilatation, was increased after 8-wk treatment with 40 mg tamoxifen daily (223), which suggests effects of endogenous testosterone involving aromatization although a direct estrogenic effect of the drug, a partial estrogen agonist, cannot be excluded. Hence, within the physiological range, testosterone impairs FMD, although the involvement of aromatization, 5-reduction, AR, or nongenomic androgen effects remains to be clarified.

In healthy, community-dwelling older men (over the age of 60 yr) with mild age-related lowering of blood testosterone concentrations, administration of transdermal testosterone for 1 yr (228) or recombinant human chorionic gonadotropin (229) or transdermal DHT gel (230) for 3 months had no significant effect on vascular reactivity. The latter study using DHT, a nonaromatizable androgen, indicates that the unimproved vascular reactivity in the two studies using testosterone was unlikely to be due to the balancing effect of estradiol via aromatization from testosterone. These findings in older men are best explained by their not being sufficiently androgen deficient, or the treatments not being used to produce sufficiently high androgen exposure, to change vascular reactivity. Alternatively, the effects of age may not be reversible by modest net changes in androgen exposure.

By contrast, vascular reactivity is increased by long-term administration of high-dose estrogens to genetic males (M2F transsexuals; Refs. 231, 232, 233), by 8-wk oral estradiol valerate treatment in older men castrated for advanced prostate cancer (234), and by parenteral administration of low-dose estradiol to healthy young men (235). Acute administration of estradiol had no effect in healthy young men (236), and FMD was absent (although nitrate- and estradiol-induced dilatation was present) in a young man with a nonfunctional, mutated ER gene (237). These findings that estradiol, mediated probably via ER in endothelial cells, augments vascular reactivity in men of all ages suggest that aromatization contributes to the vascular reactivity effects of exogenous and endogenous testosterone.

Administration of testosterone to women has less clear results. Genetic females having long-term administration of testosterone (F2M transsexuals) maintaining male blood testosterone concentrations have larger brachial artery diameter and reduced nitrate-induced response, but FMD was not significantly different from age-matched female controls (238). For estrogen-treated postmenopausal women having parenteral testosterone (producing a 5-fold elevation to supraphysiological blood testosterone concentrations for women), FMD was apparently increased, although the small effect size was difficult to interpret due to baseline mismatch for vascular reactivity (239). The effects of age, aromatization, and testosterone dose in these contrasting findings remains unclear.

	V. Coronary Artery Disease

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
The relationship of androgens to coronary artery disease has been well reviewed (240, 241, 242). Observational studies show a consistent inverse relationship between endogenous testosterone and adverse cardiovascular events (240, 243, 244, 245, 246). These findings may be interpreted as suggesting the testable hypothesis that chronically lowered blood testosterone may increase risk of cardiovascular disease. However, such findings from cross-sectional studies cannot distinguish the direction of causality (either of which is plausible) or exclude a common cause. The opposite interpretation is that blood testosterone is mildly lowered due to heart disease, as occurs for many chronic disorders (247, 248, 249, 250). Longitudinal studies do not support the predictive value of lowered blood testosterone concentration for further cardiovascular events (240, 251, 252), which favors the decrease in cross-sectional studies being an effect, rather than a cause. Nevertheless, the only definitive test of this important concept is a prospective interventional study of sufficient power and duration of surveillance to estimate or exclude an important protective effect size.

An important predictive relationship for blood DHEA sulfate (DHEAS) with further cardiovascular disease was first reported by the Rancho Bernardo study, which found that low blood DHEAS concentration predicted cardiovascular disease 12 yr later among community-dwelling older men, but not women (253). Subsequent observational studies confirmed these findings, albeit with a lower risk (252), whereas other similar prospective studies with more than 5-yr follow-up fail to confirm the original observation (254, 255, 256). Further analysis of the original study cohort at 19 yr has attenuated and qualified the risk (257). The apparent protective effects of DHEA remain hard to explain. DHEA and its sulfated ester DHEAS are weak androgens of adrenal origin that circulate at high blood levels in young adults before undergoing a steep decline from the third decade of life. Yet, DHEA has no convincing hormonal effects in its own right (other than due to conversion to bioactive steroids), consistent with the absence of a specific DHEA receptor or distinctive functional effects. Preliminary reports of DHEA binding (77, 258, 259, 260) have not yet led to characterization of a specific DHEA receptor. However, given the plethora of orphan receptors in the nuclear receptor gene superfamily (261), a specific DHEA receptor cannot be discounted. Similarly, there is evidence for DHEA interacting with neurotransmitter (N-methyl-D-aspartate , -aminobutyric acid_A) receptors (262), having vasodilator properties (192, 205, 263) and many other nonspecific biological effects (264), but none that convincingly explains cardioprotective effects. Although mechanistic studies have still not identified plausible explanatory mechanisms for protective effects of DHEAS, further studies are warranted. Alternatively, methodological factors may be the explanation. For example, the very steep age-related decline in DHEAS concentrations and complex interrelationships with other age-related cardiovascular risk factors may be difficult to fully account for confounding by age despite sophisticated analyses (252). It remains to be clarified whether predictive effects of DHEAS on cardiac mortality reflect confounding by the strong age dependence of its circulating concentration (265) or other factors such as cardiac failure, which lowers DHEAS in proportion to its severity (266).

Interventional studies of androgen effects on symptomatic coronary artery disease are limited (Table 2). Three RCTs of chronic androgen therapy involving objective clinical cardiovascular end-points have been reported. Earlier studies having no controls (267) or only ad hoc controls (268, 269) reported that androgen therapy improved symptomatic angina (270). The three well-controlled studies consistently report improvement in objective measures of cardiac ischemia (exercise stress testing) with subjective improvements with 2- to 12-wk testosterone therapy. The first study randomized 50 symptomatic men with cardiographic evidence of ischemia (postexercise ST segment depression) to weekly injections of testosterone cypionate (200 mg) or oil vehicle for 8 wk (271). Testosterone caused a highly significant reduction (32% at 4 wk, 51% at 8 wk) in postexercise ST segment depression compared with placebo, which had no effect (<2%). These findings were confirmed by a placebo-controlled, crossover study of 62 older men with established ischemic heart disease randomized to treatment with either testosterone undecanoate (120 mg/d for 2 wk, then 40 mg/d for 2 wk) or placebo, and then crossed over to the other treatment after a 2-wk washout period (272). Dramatic improvement in cardiac ischemia in subjective (77% vs. 7% with angina symptoms) and objective criteria (electrocardiogram, 69% vs. 8%; Holter, 75% vs. 8%), but no change in cardiac function (echocardiography) was observed. This latter study was apparently unblinded, and the objective scales were not described; in addition, another report gives an inconsistent account of the placebo treatment (273). Most recently, a third study involved 46 men with stable angina randomized to receive daily testosterone (5 mg) transdermal patch or matching placebo for 12 wk in addition to their current antianginal therapy (274). Testosterone lengthened time to ST segment depression and improved subjective pain perception and physical role function compared with placebo. In concert, these studies suggest that testosterone is a coronary vasodilator in men with established atherosclerosis. The consistent improvement in objective measures of cardiac function indicates that, despite the fact that mood elevating and motivational effects of testosterone might enhance effort-dependent exercise tests, such subjective reactions to testosterone cannot explain all cardiac effects of androgens.

Direct arterial infusion of testosterone causes acute coronary vasodilatation. Intracoronary infusions of testosterone (3 min) at physiological concentrations induces coronary artery dilatation and increased coronary blood flow in men with established coronary artery disease (278). Intravenous testosterone infusions can acutely enhance brachial artery flow-mediated dilatation, but only at supraphysiological concentrations (224). These findings are consistent with numerous experimental findings that testosterone causes acute coronary dilatation (149, 186, 192, 197).

In summary, these findings suggest that, at high doses, testosterone is a coronary vasodilator with effects comparable to conventional antiischemic drugs. None of the clinical studies clarify the involvement of aromatization, 5-reduction, AR, or nongenomic mechanisms in testosterone effects. Unless the vasodilator properties of testosterone extend to lower concentrations (206), these findings cannot explain the clinical trial findings with lower testosterone doses, and additional effects may be involved. Whether these findings with high-dose testosterone have practical implications for development of a novel antiischemic therapy is uncertain. On the basis of existing epidemiological findings, the hypothesis that testosterone may ameliorate progression of cardiac ischemia warrants further clinical studies.

	VI. Hypertension

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
The role of reproductive hormones and gender differences in hypertension has been well reviewed recently (279, 280). Blood pressure is higher in men than women from puberty onward (281, 282) so that the prevalence and complications of hypertension exhibit consistent gender differences. Animal models suggest that this is primarily due to testosterone increasing blood pressure, but the mechanism remains only partly understood. In men, small studies of older men castrated for prostate cancer show increased large artery stiffness (283, 284) but no consistent changes in blood pressure (221, 283, 284, 285). It is possible, however, that aging effects overshadow those of testosterone. Epidemiological findings that testosterone and blood pressure are inversely related in populations of men (251, 286) are supported by metaanalysis (287) and other study (249) findings that chronic diseases, including hypertension, accelerate the age-related decline in blood testosterone concentration. With advancing age, blood pressure rises progressively so that by the seventh decade blood pressure and prevalence of hypertension are similar in men and women. The absence of blood pressure changes in longitudinal studies of the menopausal transition, together with the minimal effects of estrogens on blood pressure (280), suggests that catch-up in older women’s blood pressure may reflect an effect of age rather than estrogen deficiency.

In untreated hypertensive men, sexual function (288) and blood testosterone concentrations (288, 289, 290, 291) are mildly reduced within the eugonadal reference range. There is a high prevalence of erectile dysfunction (ED) among treated hypertensive men, an adverse effect that reduces quality of life and therapeutic compliance (292). Although all classes of antihypertensive drugs have been linked with ED, the most frequent mechanism appears to involve unrecognized atherosclerotic pelvic arterial insufficiency, which reduces cavernosal blood inflow particularly after lowering of systemic blood pressure regardless of antihypertensive drug class (293). Prospective studies of hypertensive patients starting antihypertensive therapy confirm that most drugs can reduce sexual activity (294, 295) and blood testosterone concentrations. These small reductions in blood testosterone concentration are most probably the consequence, rather than the cause, of reduced sexual activity (296). Whether any antihypertensive drug class has consistent benefit in ED risk, at equivalent hypotensive efficacy, remains to be established in prospective controlled studies with careful documentation of sexual function before and after treatment.

All major rat models for hypertension (SHR, Dahl salt-sensitive, deoxycorticosterone acetate-induced, NZ genetically hypertensive) show consistently that males have higher blood pressure than age-matched females. Hypertension is prevented by orchidectomy (but not oophorectomy) of young hypertension-prone SHR rats and is reproduced by testosterone treatment of castrate males or females (279, 280). Introducing the tfm X chromosome (including a mutated, nonfunctional AR) into the SHR model abolishes the gender difference in blood pressure (11), as does flutamide but not finasteride (297), indicating involvement of the AR but not 5-reduction. Neonatal androgen imprinting determines the sexually dimorphic pattern of blood pressure as a single neonatal testosterone dose administered to newborn females increased their blood pressure to male levels at maturity (298). The nature of the testosterone effect remains elusive, although kidney transplantation demonstrates the involvement of an extrarenal factor (12), an endothelium-derived substance causing hyperpolarization of vascular smooth muscle involving potassium channels (13). Evidence for key involvement of the renin-angiotensin system, based on effects of an angiotensin I-converting enzyme (ACE) inhibitor (299), is less convincing given the nonspecific hypotensive effects of ACE blockade, and further studies using transgenic models would be more definitive. The hypothesis that the role of testosterone in hypertension-prone rats may reflect variations in tissue androgen sensitivity (279) warrants further analysis, including the association of the CAG triplet repeat functional polymorphism in the human AR that influences tissue androgen sensitivity (300). Similar findings are reported for the salt-sensitive hypertensive male rat model with testosterone regulating renal _2B adrenoreceptors (301). There is also evidence for a rat Y chromosome locus producing gender-selective hypertension mediated by testosterone and the AR (14) and involving sympathetic nervous system activation (302). The responsible rat locus, its human homolog, and the specific mechanisms remain to be identified.

Few studies have examined the gender differences in mouse blood pressure. Gonadectomy reduces blood pressure in mature male but not female mice (303) and abolishes the gender difference in plasma ACE activity (304) and cardiac ventricular ACE mRNA (305). Further studies using the wealth of genetic tools available to study molecular physiology of blood pressure in the mouse are becoming available (306). Well-developed technologies exist to introduce transgenes with control of spatial and temporal patterns to create global, tissue- or cell-specific gene inactivation with or without triggering of gene inactivation by molecular switches (306). Additionally, genotypes can be modified or rescued by crossbreeding with other informative genotypes providing unique physiological precision and incisiveness. Further application of mouse genetics to understanding the sexually dimorphic renin-angiotensin system and its role in the maintenance of normal and elevated blood pressure is likely to be highly informative on how gender and androgens modulate this system (307).

	VII. Cardiac Hypertrophy and Failure

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
The effects of gender and reproductive hormones on cardiac mass have been reviewed (308). Even after allometric adjustment for gender differences in overall body size (itself androgen dependent), left ventricular mass begins to differ between men and women from puberty onward and continues to diverge throughout life (308). The latter remains controversial because of the complexity of accounting for age-dependent accumulation of pathologies (both clinically overt and subclinical) that influence cardiac mass (e.g., ischemia, hypertension). This has led to the hypothesis that testosterone influences human left ventricular hypertrophy (309).

A variety of rat models for cardiac hypertrophy and heart failure involving pressure (aortic banding) or volume (fistula) overload report males showing poorer survival and cardiac function adaptation (310). After experimental myocardial infarction, testosterone is reported to cause both cardiac hypertrophy and improved cardiac function (311) or high risk of acute cardiac rupture and worse cardiac function (312). Further studies standardizing the cardiac lesion and androgen regimen as well as evaluating the role of testosterone metabolites and AR are required to clarify and extend these findings. A seminal study of the latter issues highlights the emerging importance of local testosterone metabolism in modulating tissue-specific androgen action (313). This systematic review of cytochrome P-450 monooxygenase gene expression and activity in human and rodent (SHR) cardiac hypertrophy observed increases in aromatase (CYP19) and 5-reductase (but not other steroid metabolizing enzymes 3ß- and 17ß-hydroxysteroid dehydrogenase isoforms) as well as AR. Hence, net androgen action in the heart and with cardiac disease may be influenced by tissue-specific variations in AR, androgen activating enzymes as well as AR coregulators, providing a range of novel therapeutic targets.

Genetic mouse models for cardiac hypertrophy and failure are being developed (314), but at present little is known regarding the role of gender or androgens in the pathogenesis of cardiac hypertrophy or failure. A gender difference in ventricular repolarization rate due to a potassium channel (Kv1.5) is reported to be androgen dependent in mice (315).

Blood testosterone concentrations are reduced in men with cardiac failure of any etiology, depending on the severity of the chronic heart failure. In end-stage cardiac failure, lowered blood testosterone concentration is improved with chronic mechanical circulatory support (316), whereas in men with stable cardiac failure, the reduction in blood testosterone concentrations is modest (317) or nil (318, 319). Although these changes may represent the hypothalamic reaction to severe chronic illness (320), a preliminary report of a pilot study that randomized 20 men with chronic heart failure to receive weekly injections of testosterone enanthate (100 mg) or placebo for 12 wk found that testosterone treatment significantly improved left ventricular ejection fraction and exercise capacity compared with placebo (321). A larger placebo-controlled study of transdermal testosterone study is under way (T. H. Jones, personal communication), and the effects of androgens on the cachexia of severe cardiac failure (322) would be of interest.

	VIII. Cerebrovascular Disease

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
A key issue in understanding the relationship of androgens to extracardiac atherosclerosis is the assumption of a unitary atherosclerotic disease process in all arteries. This is supported by the similar pathological appearances of all stages at different sites (323, 324, 325), the common localization of plaques in areas of arterial wall stress and stretch (326), and similar risk factor patterns for atherosclerosis in different arterial trees (327). Doubts about this assumption arise chiefly from differences in relative importance of specific risk factors from individual observational studies (328), but systematic differences appear to be few.

The age-adjusted prevalence of stroke is 1.25- to 2-fold higher in men than in women (329, 330, 331). Like coronary artery disease, cerebrovascular disease increases with age, with a doubling of stroke rates in both man and women for each decade after the age of 55 yr (331). Although data are sparse, there is no evidence of acceleration in stroke incidence specifically related to menopause rather than to advancing age. Whereas coronary artery disease has largely singular (thrombosis) pathology, cerebrovascular disease (stroke) can be due to either thromboembolism (75%), the cerebral manifestation of generalized atherosclerosis, or hemorrhage (25%), which is more related to genetics and hypertension. Thus, the role of androgens in stroke pathogenesis may differ according to the underlying pathology. Nevertheless, the minority of population-based studies that examine specifically ischemic stroke (determined at autopsy or by radiological imaging) confirm that men have more ischemic strokes than women (332, 333).

In case-control studies, male stroke survivors have lower blood (334, 335, 336) and cerebrospinal fluid (335) testosterone concentrations, similar to observations after myocardial infarction (240). Whether lowered blood testosterone reflects a preexisting state predisposing to stroke or an acute reaction to stroke is not known. This issue could be clarified by the predictive value of blood testosterone concentration for stroke from ongoing prospective studies. Although prospective data are not yet available, a cross-sectional population-based study found that endogenous testosterone was inversely related to carotid intima media thickness (337), a strong predictor of subsequent stroke and other atherosclerotic vascular events (338). Stroke is associated with high doses or abuse of synthetic androgens with case reports in three athletes and four men with hypoplastic anemia by 1993 (339) and another five, including two with underlying medical disorders subsequently (340, 341, 342, 343, 344). Only a single case associated with testosterone is reported, involving overdose in a hypogonadal adolescent (345). The unknown denominator of usage from which these cases are drawn makes it difficult to judge the actual clinical risks of stroke associated with androgen use, particularly with standard testosterone doses.

Only one well-controlled clinical study has examined the effects of testosterone on cerebrovascular disease. Forty postmenopausal women receiving stabilized estradiol/progestin therapy were randomized to receive either oral testosterone undecanoate (40 mg/d) or no treatment in a nonmasked study for 8 months (346). Five of the 20 (25%) women on testosterone withdrew due to androgenic side effects or independent medical advice. Testosterone treatment, producing a 4-fold increase in blood testosterone, produced a 6% increase in the pulsatility index of the middle cerebral artery, but not of the internal carotid artery. The clinical significance of this small increase in middle cerebral artery resistance is unclear. No controlled studies of androgens with cerebrovascular end-points in men are reported.

The effects of testosterone on cerebral vasculature are poorly defined. One rat study reported that testosterone increases the autoregulatory myogenic tone of cerebral arteries through an endothelium-dependent mechanism independent of NOS and possibly mediated by other vasoactive substances (e.g., prostanoids or endothelins) that inhibit vascular smooth muscle K channels (347). Effects of higher (micromolar) concentrations of testosterone, which are vasodilatory in all other arterial beds studied, have not been reported in the cerebral vasculature.

Studies of stroke-prone SHR rats report that males had higher blood pressure and stroke rate and shorter life span than females (348). These outcomes were not influenced by castration; estrogen treatment of castrate males reduced stroke rate and lengthened life span to match female levels, whereas testosterone treatment of females reproduced intact male stroke rate and life span (348). These findings are consistent with evidence that hypertension in SHR rats is testosterone mediated (see Section VI), and stroke-proneness is due largely to hypertension.

Estrogen-mediated neuroprotection has been described (349, 350), including in male rats where it is independent of endogenous testosterone (351). Testosterone enhances neuronal survival and regeneration after ischemic and toxin-mediated damage (352, 353, 354, 355, 356), effects that involve aromatization to estradiol (357) exploiting the neuroprotective effects of the phenolic A ring (358). On the contrary, however, it is claimed that ischemia-reperfusion injury (359, 360), in which reactive hyperemia after reperfusion leads to vascular damage and leakage, might involve vasodilatory effects of testosterone (360). This seems unlikely given the high testosterone concentrations required for vasodilatation together with the profound reduction in blood testosterone concentrations during acute illness (361). Nevertheless, because acute androgen blockade appears to improve recovery from trauma and shock (362), studies of pharmacological androgen blockade might be of interest.

In summary, whether the lowered blood testosterone concentrations in male stroke survivors reflect a cause or effect of stroke remains unclear. This should be resolved by prospective studies of the predictive value of blood testosterone concentrations for future stroke. A significant predictive value might justify a placebo-controlled trial of androgen therapy of modest duration in a high-risk population aiming to reduce stroke risk.

	IX. Peripheral Arterial Disease

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
Peripheral arterial disease (PAD), as the manifestation of atherosclerotic arterial disease affecting the pelvis and legs, has been comprehensively reviewed recently (363, 364). Although it is generally assumed that the atherosclerotic pathogenesis of PAD is similar to that in the cardiac and cerebral circulations, fewer observational or interventional studies of PAD are available to evaluate this empirically. This reflects the neglected clinical status of PAD, which remains undertreated (365, 366) despite high mortality and morbidity (363, 364), a perspective also reflected in the limited contributions to research on atherosclerosis in this area.

Observational studies show a crude prevalence of PAD that is 2- to 3-fold higher in men than women (363) and even higher (6-fold) for abdominal aortic aneurysm (367) in larger, population-based studies. The higher gender disparity in abdominal aortic aneurysm may be due to more sensitive and specific detection using ultrasound in larger population studies. When analysis of PAD is restricted to studies using standardized diagnostic criteria for asymptomatic (ankle-brachial index) or symptomatic (World Health Organization/Rose questionnaire for intermittent claudication) disease in population-based studies (rather than high-risk subpopulations), the age-specific prevalence is closer in men and women, but it ranges from 3–19% between centers (368). The weaker evidence for a gender disparity gap in PAD is more likely to reflect fewer high-quality studies rather than any fundamental differences in pathogenesis of PAD compared with cardiac and cerebral vascular atherosclerosis.

Interventional studies on the role of androgen therapy in PAD are limited and largely negative. Empirical androgen therapy to treat claudication was first used over six decades ago (267, 369), soon after the first clinical availability of testosterone (370). Four randomized controlled studies performed over 30 yr ago are consistent in showing no benefit for androgen therapy in PAD. The first study randomized (by alternate allocation) 39 men with claudication to treatment with testosterone enanthate (200 mg/wk for 3 wk, then fortnightly) or placebo oil vehicle injections for 6 months (371). Treatment produced no significant benefit over placebo in symptoms, walking time to onset of symptoms, hand-grip strength, venous filling time, pulse amplitude or side effects, despite significant improvement in leg muscle blood flow (Xenon clearance) and increased libido. The second double-blind study randomized 44 nondiabetic men with claudication to receive a lower androgen dose (testosterone isobutyrate, 300 mg) or control (meprobamate as a placebo) injected every 14 d over a 12-wk study period before crossover to the other treatment (372). Testosterone treatment did not alter foot pulses, metronome walking distance (a measure of claudication), plethysmographic parameters, or symptoms, although body weight was increased. However, carryover effects leading to a null bias may not have been excluded by a washout period, the length of which was not stated. A third study randomized 26 patients to injections of 100 mg testosterone propionate or placebo oil vehicle three times weekly for 2–6 months without any subjective or objective benefit (373). Finally, the fourth double-blind study treated 22 nondiabetic men with claudication with either testosterone (100 mg/d plus various other hormones 6 d/wk) or placebo vehicle injections for 6 wk (374). No randomization was specified, and no difference in pain or standardized walking test was reported. In summary, the few available controlled studies from three decades ago lack sophisticated study design or methodology by current standards (375), but nevertheless androgen therapy has demonstrated neither significant benefit nor much promise in treatment of PAD.

Comparing the placebo-controlled clinical trials, there is a striking discrepancy between these consistently negative findings for testosterone treatment and the equally consistent alleviation of cardiac ischemia by testosterone. This may reflect different caliber vessels involved with coronaries possessing more dynamic vasodilatory capacity compared with the larger aortoiliac and femoral vessels in PAD. If so, this also favors the interpretation that beneficial testosterone effects in myocardial ischemia are more likely due to reversal of cardiac ischemia, rather than nonspecific mood elevation or improved pain tolerance because the latter might be equally likely in claudication.

	X. Erectile Dysfunction

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
Vasculogenic ED, the most prevalent cause of erectile failure, has a strong but insufficiently appreciated relationship to atherosclerosis. The penis is a highly specialized vascular bed, and erection is a vascular hydraulic mechanism activated by neural triggering that coordinates arteriolar dilatation, smooth muscle relaxation, and venous constriction (376). This mechanism involves NO release (377), increased cytosolic cyclic GMP (378), and decreased calcium (379) in smooth muscle cells leading to vasodilatation and cavernosal filling (380). Medical treatment of ED was revolutionized by the advent of a highly effective oral drug (sildenafil; Refs. 380 and 381) targeting this pathway through the inhibition of tissue-selective, type 5 phosphodiesterase inhibitor that enhanced cyclic GMP action via inhibition of its metabolism (382).

ED is highly age-dependent and remarkably frequent from midlife onward. Among American men aged 40–70 yr, approximately 10% have severe ED, and approximately 50% have some degree of ED (383). ED is now understood to be mostly due to organic, primarily vasculogenic, rather than psychogenic factors or androgen deficiency. A major factor in vasculogenic ED is arterial insufficiency due to the pelvic arterial variant of atherosclerotic vascular disease involving aortoiliac (Leriche syndrome), smaller conductance vessels together with endothelial dysfunction (384). Animal models show conclusively that atherosclerosis of the lower aorta, iliac, and penile arteries causes erectile failure in rabbits (385) and monkeys (386). The close relationship of ED to PAD is reflected by the efficacy of a type 3 phosphodiesterase inhibitor, cilostazol, in medical therapy of claudication (387, 388).

Major risk factors for ED, notably aging, smoking, hyperlipidemia, hypertension, and diabetes, are similar to those for cardiovascular disease (384, 389). Consequently, men with ED have higher risk for other atherosclerotic diseases, and men with coronary, cerebral, or peripheral atherosclerotic vascular disease are at higher risk for ED (390). This suggests the following: 1) ED may be a sentinel feature of atherosclerosis with prognostic significance for men’s general health (391), and 2) primary prevention may retard progression of ED (392). Whether lipid-lowering pharmacotherapy can prevent ED is clouded by claims that the most effective agents (statins) cause ED as a common side effect (384), although available evidence is inconclusive (393, 394, 395) because evaluating causality for drug-associated ED is frequently problematic without thorough characterization of pretreatment erectile function. This limits the utility of secondary analyses of completed large-scale placebo-controlled statin studies unless new-onset ED can be referred to an appropriate denominator with well-characterized erectile function. Hence, formal evaluation of whether ED is a sentinel event for generalized atherosclerosis requires a large-scale, randomized, placebo-controlled prospective study.

The relationship of androgens to vasculogenic ED might be considered similar to that with atherosclerosis elsewhere, but this is largely overshadowed by the stronger relationships of androgens to aspects of sexual function other than erection. The primary role of androgens in human male sexual function is in maintenance of libido (396, 397). Androgen effects on human erectile function are more complex, with spontaneous nocturnal erections being more androgen-dependent than psychogenic erections (398). In experimental animal models, there is evidence that androgens influence pelvic autonomic nerves (399) and penile vasculature and smooth muscle (400). In humans, however, there still remains scant evidence regarding direct androgen effects on the neurovascular mechanisms subserving erectile function (400), a limitation that partly reflects the difficulty of access to relevant human tissues. Excluding the small minority (<5%) of men presenting with ED due to androgen deficiency from pituitary or testicular pathologies (401), most men with ED have normal or minimal reduction in blood testosterone concentration. The small reduction in blood testosterone concentration among men with ED who are not frankly androgen deficient may reflect sexual inactivity itself rather being its cause (296). As a result, empirical testosterone treatment in non-androgen-deficient men with ED may activate sexual behavior without improving erectile function or satisfaction compared with placebo (402). Particularly outside clinical trial settings, an unrecognized but strong placebo response is likely to be invoked. Such widening of the gap between libido and performance may even be considered mental cruelty, rather than compassionate medical care.

The role of endogenous or exogenous testosterone in the rate of progression of vasculogenic ED remains difficult to study. Endothelial dysfunction, involving disrupted release of vasoactive mediators from the vascular endothelium, is an important early feature of ED as well as an important predictor and pathogenic mechanism in cardiovascular disease. Both forms of endothelial dysfunction have been linked by the hypothesis that defective NO activity may be a common mechanism (403). A preliminary evaluation in men with diabetes found a relationship between biochemical indices of endothelial function (thrombomodulin, cell-adhesion molecules) with ED (404). Further evaluation of this hypothesis using more specific and sensitive hemodynamic measures of peripheral endothelial dysfunction (FMD) in men with ED may shed light on any role of androgens in the progression of ED. Whether androgen-mediated inhibition of FMD in brachial vessels has any counterpart in the endothelium of human penile vasculature and cavernosal smooth muscle remains to be studied further (405).

In summary, penile erection is a neurovascular hydraulic mechanism operating in a highly specialized arterial system. Atherosclerosis involving this arterial bed is the most frequent cause of ED, among the most common and distressing pathologies afflicting men’s later life. Considering its highly motivating potential, an issue with important public health ramifications for prevention of cardiovascular disease is whether ED can be considered a sentinel event predicting wider atherosclerotic complications and whether pharmacological antiatherogenic therapy may prevent or reverse vasculogenic ED. Overt androgen deficiency is rarely the cause of new presentations of ED and androgen replacement therapy has little role in the treatment of ED. The role, if any, of androgens in progression of vasculogenic ED is little understood and difficult to study because it is largely overshadowed by the primary effect of androgens on sexual function being on other aspects of sexual function.

	XI. Conclusion: the Present and Future

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 
In recent years, there has been a dramatic increase in research into androgen effects on the cardiovascular system. Yet, present knowledge of the role of androgens in cardiovascular physiology and disease remains fragmentary, and the best available evidence is mostly far from complete. Whereas previously androgens were considered harmful (and estrogens protective) for the cardiovascular system, current empirical findings give a far richer but more complex, and at times confusing, picture. Considerable evidence suggests that androgens have beneficial or neutral cardiovascular effects and that they exert different effects at early (plaque formation) and late (rupture, thrombosis, vasospasm) stages of atherosclerosis. Patterns of age-specific cardiovascular death rates provide little support for the gender gap being due to estrogen protection. Rather, hormonal effects may provide a head start in men at an early stage, but the subsequent tempo of atherosclerotic progression is similar in men and women. Such early hormonal effects may involve perinatal androgen imprinting or an early stage of atherosclerosis.

The estrogen protection hypothesis has been refuted, at least for oral estrogens, in men as it has in women more recently. Whether nonoral administration of tissue-specific partial estrogen agonists (selective estrogen receptor modulators), avoiding the oral route with its unavoidable first-pass hepatic overdosage, would produce more favorable outcomes is open to speculation. Considering all available evidence on androgen effects, current findings on sex hormones and heart disease better fit the hypothesis of Barrett-Connor (244) that isosexual hormone deficiency may be harmful for the cardiovascular system, whereas gender-appropriate, isosexual hormone replacement by physiological means may be beneficial or may at least reverse deleterious effects of hormone deficiency. The adverse effects of androgen abuse on the cardiovascular system remain largely anecdotal, and systematic case-control studies of former power athletes and other abusers are needed.

In vascular cells, testosterone action often involves nongenomic effects on vascular smooth muscle and sometimes aromatization for endothelial-mediated effects. Knowledge of local fine-tuning of vascular cell androgen sensitivity, in different arterial beds and under different physiological and pathological conditions, by genomic and hormonal mechanisms still remain to be defined. Advancing knowledge in this area seems likely to provide not only valuable physiological insight but also novel therapeutic approaches based on tissue-specific nonsteroidal androgens. Nongenomic vasodilator effects of high testosterone concentrations partly explain objective improvement in exercise-induced cardiac ischemia. By contrast, testosterone treatment does not improve PAD or ED, whereas androgen effects on cerebral vessels have been little reported. Testosterone is a major pathogenic factor in experimental rodent models of hypertension, but the corresponding evidence in humans is too limited to identify any specific role of androgens in human hypertension or heart failure.

In the future, the promising high-impact areas for further research include a characterization of the nongenomic mechanisms of androgen effects, identification of androgen target genes, the wider use of gene targeting in mouse models using temporal and spatial control of gene expression to dissect complex pathways of vascular cell interactions, the regulation and dynamic roles of AR coregulators and other determinants that modulate tissue androgen sensitivity, and the development of tissue-specific nonsteroidal androgens. Among key clinical areas, the role of adjuvant androgen therapy, antiandrogens, and especially tissue-specific partial androgen agonists (selective AR modulators, designer androgens) for stable ischemic heart disease, heart failure, hypertension, and slowing progression of native and graft atherosclerosis are promising areas. With regard to clinical trials of androgen therapy in aging or other clinical settings, variations of testosterone dose or blood concentrations within the physiological male range have no predictable deleterious short-term or medium-term cardiovascular effects. This indicates sufficient safety for androgen use in controlled clinical trials in aging and other emerging applications of androgen therapy. Yet, the long-term safety of androgens is not sufficiently established for wider usage in male aging to be considered an acceptable risk for population health. Still less well defined is the safety of androgen abuse, particularly long-term.

The recent flourishing of research into androgen effects on the cardiovascular system has fostered new concepts and approaches that promise to provide greater insight into the basis of the gender gap in cardiovascular disease and androgen action in general, as well as greater confidence in how to ensure safety in the widening opportunities for adjuvant use of androgens in medicine.

	Acknowledgments

 
We acknowledge the intellectual stimulation and long-term collaboration of our cardiology colleague Prof. David Celermajer. We thank an anonymous reviewer for suggesting congenital adrenal hyperplasia as a natural model for perinatal androgen imprinting in females.

	Footnotes

 
This work was supported in part by grants from the National Health and Medical Research Council of Australia, the National Heart Foundation, and the Merck Medical School Program.

Abbreviations: ACE, Angiotensin I-converting enzyme; ApoE, apolipoprotein E; AR, androgen receptor(s); DHEA, dehydroepiandrostendione; DHEAS, DHEA sulfate; DHT, dihydrotestosterone; ED, erectile dysfunction; ER, estrogen receptor(s); F2M, female to male; FMD, flow-mediated dilatation; GDP, Gross Domestic Product; HUVEC, human umbilical vein endothelial cells; LDL, low-density lipoprotein; NO, nitric oxide; NOS, NO synthase; PAD, peripheral arterial disease; RCT, randomized controlled trial; SHR, spontaneously hypertensive rat; T-BSA, testosterone rendered membrane-impermeable by conjugation to BSA; VCAM-1, vascular cell adhesion molecule-1.

	References

Top Abstract I. Introduction II. Gender, Life Span,... III. Newer Aspects of... IV. Vascular Biology V. Coronary Artery Disease VI. Hypertension VII. Cardiac Hypertrophy and... VIII. Cerebrovascular Disease IX. Peripheral Arterial Disease X. Erectile Dysfunction XI. Conclusion: the Present... References

 

1. Murray CJL, Lopez AD 1996 The global burden of disease. Geneva: World Health Organization
2. Willius FA, Dry TJ 1948 A history of the heart and the circulation. Philadelphia: WB Saunders Co.; 15
3. Kalin MF, Zumoff B 1990 Sex hormones and coronary disease: a review of the clinical studies. Steroids 55:330–352[CrossRef][Medline]
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613[Abstract/Free Full Text]
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333[Abstract/Free Full Text]
6. Handelsman DJ 1998 The safety of androgens: prostate and cardiovascular disease. In: Wang C, ed. Male reproductive function. Boston: Kluwer Academic Publishers; 173–190
7. Weidemann W, Hanke H 2002 Cardiovascular effects of androgens. Cardiovasc Drug Rev 20:175–198[Medline]
8. 2002 World Population Data Sheet. Washington, DC: Population Reference Bureau
9. The World Health Report 2002. Geneva: World Health Organization
10. Owens IP 2002 Ecology and evolution. Sex differences in mortality rate. Science 297:2008–2009[Free Full Text]
11. Ely DL, Salisbury R, Hadi D, Turner M, Johnson ML 1991 Androgen receptor and the testes influence hypertension in a hybrid rat model. Hypertension 17:1104–1110[Abstract/Free Full Text]
12. Harrap SB, Wang BZ, MacLellan DG 1992 Renal transplantation between male and female spontaneously hypertensive rats. Hypertension 19:431–434[Abstract/Free Full Text]
13. Honda H, Unemoto T, Kogo H 1999 Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 34:1232–1236[Abstract/Free Full Text]
14. Ely D, Turner M, Milsted A 2000 Review of the Y chromosome and hypertension. Braz J Med Biol Res 33:679–691[Medline]
15. Kromhout D, Menotti A, Kesteloot H, Sans S 2002 Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation 105:893–898[Free Full Text]
16. Barrett-Connor E 1997 Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95:252–264[Free Full Text]
17. Sackett DL 1979 Bias in analytical research. J Chronic Dis 32:51–63[CrossRef][Medline]
18. Tracy RE 1966 Sex difference in coronary disease: two opposing views. J Chronic Dis 19:1245–1251[CrossRef][Medline]
19. Furman RH 1968 Are gonadal hormones (estrogens and androgens) of significance in the development of ischemic heart disease. Ann NY Acad Sci 149:822–833[CrossRef][Medline]
20. Heller RF, Jacobs HS 1978 Coronary heart disease in relation to age, sex, and the menopause. Br Med J 1:472–474
21. Tunstall-Pedoe H 1998 Myth and paradox of coronary risk and the menopause. Lancet 351:1425–1427[CrossRef][Medline]
22. Rossouw JE 2002 Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 53:550–557[Free Full Text]
23. Coronary Drug Project Research Group 1973 The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 226:652–657[Abstract/Free Full Text]
24. The Veterans Administration Co-operative Urological Research Group 1967 Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011–1017[Medline]
25. Nieschlag E, Nieschlag S, Behre HM 1993 Lifespan and testosterone. Nature 366:215[Medline]
26. Jenkins JS 1998 The voice of the castrato. Lancet 351:1877–1880[CrossRef][Medline]
27. Paternostro G 1994 Longevity and testosterone. Nature 368:408[Medline]
28. Smith SM 1994 Statistical scrotal effect. Nature 368:501–502[Medline]
29. Hamilton JB, Mestler GE 1969 Mortality and survival: comparison of eunuchs with intact men and women in a mentally retarded population. J Gerontol 24:395–411
30. Hawke CC 1950 Castration and sex crimes. J Kans Med Soc 51:470–475
31. Eyman RK, Grossman HJ, Chaney RH, Call TL 1990 The life expectancy of profoundly handicapped people with mental retardation. N Engl J Med 323:584–589[Abstract]
32. Hamilton JB, Hamilton RS, Mestler GE 1969 Duration of life and causes of death in domestic cats: influence of sex, gonadectomy, and inbreeding. J Gerontol 24:427–437
33. Michell AR 1999 Longevity of British breeds of dog and its relationships with sex, size, cardiovascular variables and disease. Vet Rec 145:625–629[Abstract/Free Full Text]
34. Waters DJ, Shen S, Glickman LT 2000 Life expectancy, antagonistic pleiotropy, and the testis of dogs and men. Prostate 43: 272–277
35. Talbert GB, Hamilton JB 1965 Duration of life in Lewis strain of rats after gonadectomy at birth and at older ages. J Gerontol 20:489–491[Medline]
36. Quigley CA, DeBellis A, Marschke KB, El-Awady MK, Wilson EM, French FF 1995 Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16:271–321[Abstract/Free Full Text]
37. van Kesteren P, Asscheman H, Megens JAJ, Gooren LJG 1997 Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 47:337–342[CrossRef][Medline]
38. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52:595–600[CrossRef][Medline]
39. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581–586[CrossRef][Medline]
40. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57:505–513[Medline]
41. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556–560[Abstract/Free Full Text]
42. Wild S, Pierpoint T, Jacobs H, McKeigue P 2000 Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 3:101–105
43. Birdsall MA, Farquhar CM, White HD 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126:32–35[Abstract/Free Full Text]
44. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599–604[Medline]
45. Rockhold RW 1993 Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 33:497–520[CrossRef][Medline]
46. Melchert RB, Welder AA 1995 Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 27:1252–1262[Medline]
47. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ 1998 The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41:1–15[Medline]
48. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO 1996 Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 276:199–204[Abstract/Free Full Text]
49. Parssinen M, Seppala T 2002 Steroid use and long-term health risks in former athletes. Sports Med 32:83–94[CrossRef][Medline]
50. Franke WW, Berendonk B 1997 Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 43:1262–1279[Abstract/Free Full Text]
51. Sarna S, Sahi T, Koskenvuo M, Kaprio J 1993 Increased life expectancy of world class male athletes. Med Sci Sports Exerc 25:237–244[Medline]
52. Menotti A, Amici E, Gambelli GC, Milazzotto F, Bellotti P, Capocaccia R, Giuli B 1990 Life expectancy in Italian track and field athletes. Eur J Epidemiol 6:257–260[CrossRef][Medline]
53. van Saase JL, Noteboom WM, Vandenbroucke JP 1990 Longevity of men capable of prolonged vigorous physical exercise: a 32 year follow up of 2259 participants in the Dutch eleven cities ice skating tour. BMJ 301:1409–1411
54. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T 2000 Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 21:225–227[CrossRef][Medline]
55. Heinlein CA, Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175–200[Abstract/Free Full Text]
56. Gregory CW, He B, Wilson EM 2001 The putative androgen receptor-A form results from in vitro proteolysis. J Mol Endocrinol 27:309–319[Abstract]
57. Misiti S, Schomburg L, Yen PM, Chin WW 1998 Expression and hormonal regulation of coactivator and corepressor genes. Endocrinology 139:2493–2500[Abstract/Free Full Text]
58. Magklara A, Brown TJ, Diamandis EP 2002 Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer 100:507–514[CrossRef][Medline]
59. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315–4319[Abstract/Free Full Text]
60. Nelson KA, Witte JS 2002 Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 155:883–890[Abstract/Free Full Text]
61. Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, Nieschlag E 2001 The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 86:4867–4873[Abstract/Free Full Text]
62. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E 2001 The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 55:649–657[CrossRef][Medline]
63. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M, Nieschlag E 2001 Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J Clin Endocrinol Metab 86:2585–2590[Abstract/Free Full Text]
64. Walcott JL, Merry DE 2002 Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy. Vitam Horm 65:127–147[Medline]
65. Yu B, Handelsman DJ 2001 Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia. J Clin Endocrinol Metab 86:4406–4411[Abstract/Free Full Text]
66. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, Jones TK 1998 New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 8:745–750[CrossRef][Medline]
67. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD 1998 Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1–4[CrossRef][Medline]
68. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT 2002 Pharmacodynamics of selective androgen receptor modulators (SARMs). J Pharmacol Exp Ther 304:1334–1340
69. Losel R, Wehling M 2003 Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46–55[CrossRef][Medline]
70. Heinlein CA, Chang C 2002 The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 16:2181–2187[Abstract/Free Full Text]
71. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2002 Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843–846[Abstract/Free Full Text]
72. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M 2000 Multiple actions of steroid hormones–a focus on rapid, nongenomic effects. Pharmacol Rev 52:513–556[Abstract/Free Full Text]
73. Gerdes D, Wehling M, Leube B, Falkenstein E 1998 Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 379:907–911[Medline]
74. Bernauer S, Wehling M, Gerdes D, Falkenstein E 2001 The human membrane progesterone receptor gene: genomic structure and promoter analysis. DNA Seq 12:13–25[Medline]
75. Zhu Y, Rice CD, Pang Y, Pace M, Thomas P 2003 Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 100:2231–2236[Abstract/Free Full Text]
76. Luzardo OP, Machin RP, Diaz-Chico BN, Fernandez L 2000 Photoaffinity labeling identification of a specific binding protein for the anabolic steroids stanozolol and danazol: an oligomeric protein regulated by age, pituitary hormones, and ethinyl estradiol. Endocrinology 141:3377–3387[Abstract/Free Full Text]
77. Liu D, Dillon JS 2002 Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to G(i2,3). J Biol Chem 277:21379–21388[Abstract/Free Full Text]
78. Kahn SM, Hryb DJ, Nakhla AM, Romas NA, Rosner W 2002 Sex hormone-binding globulin is synthesized in target cells. J Endocrinol 175:113–120[Abstract]
79. Grino PB, Griffin JE, Wilson JD 1990 Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126:1165–1172[Abstract/Free Full Text]
80. George FW, Russell DW, Wilson JD 1991 Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5-reductase. Proc Natl Acad Sci USA 88:8044–8047[Abstract/Free Full Text]
81. Eicheler W, Tuohimaa P, Vilja P, Adermann K, Forssmann WG, Aumuller G 1994 Immunocytochemical localization of human 5 - reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J Histochem Cytochem 42:667–675[Abstract]
82. Eicheler W, Dreher M, Hoffmann R, Happle R, Aumuller G 1995 Immunohistochemical evidence for differential distribution of 5 -reductase isoenzymes in human skin. Br J Dermatol 133:371–376[CrossRef][Medline]
83. Milewich L, Kaimal V, Johnson AR 1987 Steroid 5-reductase activity in endothelial cells from human umbilical cord vessels. J Steroid Biochem 26:561–567[CrossRef][Medline]
84. Fujimoto R, Morimoto I, Morita E, Sugimoto H, Ito Y, Eto S 1994 Androgen receptors, 5-reductase activity and androgen-dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol 50:169–174[CrossRef][Medline]
85. Martel C, Melner MH, Gagne D, Simard J, Labrie F 1994 Widespread tissue distribution of steroid sulfatase, 3ß-hydroxysteroid dehydrogenase/ 5- 4 isomerase (3ß-HSD), 17ß-HSD 5-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104:103–111[CrossRef][Medline]
86. Matsuda K, Mathur RS, Ullian ME, Halushka PV 1995 Sex steroid regulation of thromboxane A2 receptors in cultured rat aortic smooth muscle cells. Prostaglandins 49:183–196[CrossRef][Medline]
87. Higashiura K, Blaney B, Morgan E, Mathur RS, Halushka PV 1996 Inhibition of testosterone 5-reductase: evidence for tissue-specific regulation of thromboxane A2 receptors. J Pharmacol Exp Ther 279:1386–1391[Abstract/Free Full Text]
88. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y 1999 Localized expression of aromatase in human vascular tissues. Circ Res 84:1285–1291[Abstract/Free Full Text]
89. Sasano H, Murakami H, Shizawa S, Satomi S, Nagura H, Harada N 1999 Aromatase and sex steroid receptors in human vena cava. Endocr J 46:233–242[Medline]
90. Murakami H, Harada N, Sasano H 2001 Aromatase in atherosclerotic lesions of human aorta. J Steroid Biochem Mol Biol 79:67–74[CrossRef][Medline]
91. Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, Chaudhuri G 2001 Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 98:3589–3593[Abstract/Free Full Text]
92. Diano S, Horvath TL, Mor G, Register T, Adams M, Harada N, Naftolin F 1999 Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6:21–28[Medline]
93. Bayard F, Clamens S, Meggetto F, Blaes N, Delsol G, Faye JC 1995 Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 136:1523–1529[Abstract]
94. Gyllenborg J, Rasmussen SL, Borch-Johnsen K, Heitmann BL, Skakkebaek NE, Juul A 2001 Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metabolism 50:882–888[CrossRef][Medline]
95. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672[Abstract/Free Full Text]
96. Morley JE, Patrick P, Perry 3rd HM 2002 Evaluation of assays available to measure free testosterone. Metabolism 51:554–559[CrossRef][Medline]
97. Edwards P, Ekins R 1988 The "Pardridge" hypotheses relating to the role of hormone binding proteins in hormone delivery: a critique. Steroids 52:367–368[CrossRef][Medline]
98. Ekins R 1990 Measurement of free hormones in blood. Endocr Rev 11:5–46[Abstract/Free Full Text]
99. Pardridge WM 1986 Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab 15:259–278[CrossRef][Medline]
100. Pardridge WM 1987 Plasma protein-mediated transport of steroid and thyroid hormones. Am J Physiol 252:E157–E164
101. Pardridge WM 1988 Selective delivery of sex steroid hormones to tissues by albumin and by sex hormone-binding globulin. Oxf Rev Reprod Biol 10:237–292[Medline]
102. Mendel CM 1989 The free hormone hypothesis: a physiologically based mathematical model. Endocr Rev 10:232–274[Abstract/Free Full Text]
103. Ekins R 1993 Analytic measurements of free thyroxine. Clin Lab Med 13:599–630[Medline]
104. Dunn JF, Nisula BC, Rodbard D 1981 Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 53:58–68[Abstract/Free Full Text]
105. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA 1999 Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. Steroids 64:100–106[CrossRef][Medline]
106. von Schoultz B, Carlstrom K 1989 On the regulation of sex-hormone-binding globulin. A challenge of an old dogma and outlines of an alternative mechanism. J Steroid Biochem Mol Biol 32:327–334
107. Pugeat M, Moulin P, Cousin P, Fimbel S, Nicolas MH, Crave JC, Lejeune H 1995 Interrelations between sex hormone-binding globulin (SHBG), plasma lipoproteins and cardiovascular risk. J Steroid Biochem Mol Biol 53:567–572[CrossRef][Medline]
108. Haffner SM 1996 Sex hormone-binding protein, hyperinsulinemia, insulin resistance and noninsulin-dependent diabetes. Horm Res 45:233–237[Medline]
109. Tchernof A, Despres JP 2000 Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 32:526–536[Medline]
110. Reventos J, Sullivan PM, Joseph DR, Gordon JW 1993 Tissue-specific expression of the rat androgen-binding protein/sex hormone-binding globulin gene in transgenic mice. Mol Cell Endocrinol 96:69–73[CrossRef][Medline]
111. Kapoor P, Luttrell BM, Williams D 1993 The free androgen index is not valid for adult males. J Steroid Biochem Mol Biol 45:325–326[CrossRef][Medline]
112. Rosner W 1997 Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 82:2014–2015[Free Full Text]
113. Winters SJ, Kelley DE, Goodpaster B 1998 The analog free testosterone assay: are the results in men clinically useful? Clin Chem 44:2178–2182[Abstract/Free Full Text]
114. Rosner W 2001 An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 86:2903[Free Full Text]
115. Barker DJP 1998 Mothers, babies and health in later life. 2nd ed. Edinburgh: Churchill Livingstone
116. Hales CN, Barker DJ 2001 The thrifty phenotype hypothesis. Br Med Bull 60:5–20[Abstract/Free Full Text]
117. Barker DJ, Forsen T, Eriksson JG, Osmond C 2002 Growth and living conditions in childhood and hypertension in adult life: a longitudinal study. J Hypertens 20:1951–1956[CrossRef][Medline]
118. Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJ 2001 Early growth and coronary heart disease in later life: longitudinal study. BMJ 322:949–953[Abstract/Free Full Text]
119. Plut C, Ribiere C, Giudicelli Y, Dausse JP 2002 Gender differences in hypothalamic tyrosine hydroxylase and (2)-adrenoceptor subtype gene expression in cafeteria diet-induced hypertension and consequences of neonatal androgenization. J Pharmacol Exp Ther 302:525–531[Abstract/Free Full Text]
120. Arnold AP, Gorski RA 1984 Gonadal steroid induction of structural sex differences in the central nervous system. Annu Rev Neurosci 7:413–442[CrossRef][Medline]
121. Rajfer J, Coffey DS 1978 Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol 16:186–190[Medline]
122. Singh J, Handelsman DJ 1999 Imprinting by neonatal sex steroids on the structure and function of the mature mouse prostate. Biol Reprod 61:200–208[Abstract/Free Full Text]
123. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS 2001 Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor : studies with ERKO and ßERKO mice. Cancer Res 61:6089–6097[Abstract/Free Full Text]
124. Gooren LJ 2001 Gender identity and sexual behavior. In: DeGroot LJ, ed. Endocrinology. 4th ed. Philadelphia: WB Saunders Co.; 2033–2042
125. Hamm Jr T, Kaplan J, Clarkson T, Bullock B 1983 Effects of gender and social behaviour on the development of coronary atherosclerosis in cynomolgus monkeys. Atherosclerosis 48:221–233[CrossRef][Medline]
126. Holm P, Andersen HL, Arroe G, Stender S 1998 Gender gap in aortic cholesterol accumulation in cholesterol-clamped rabbits: role of the endothelium and mononuclear-endothelial cell interaction. Circulation 98:2731–2737[Abstract/Free Full Text]
127. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G 1995 Gender differences in atherosclerosis: possible role of nitric oxide. J Cardiovasc Pharmacol 26:792–802[Medline]
128. Caligiuri G, Nicoletti A, Zhou X, Tornberg I, Hansson GK 1999 Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice. Atherosclerosis 145:301–308[CrossRef][Medline]
129. Tangirala RK, Rubin EM, Palinski W 1995 Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res 36:2320–2328[Abstract]
130. Trieu VN, Uckun FM 1998 Male-associated hypertension in LDL-R deficient mice. Biochem Biophys Res Commun 247:277–279[CrossRef][Medline]
131. Johnson RC, Chapman SM, Dong ZM, Ordovas JM, Mayadas TN, Herz J, Hynes RO, Schaefer EJ, Wagner DD 1997 Absence of P-selectin delays fatty streak formation in mice. J Clin Invest 99:1037–1043[Medline]
132. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK 2000 Peroxisome proliferator-activated receptor ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523–531[Medline]
133. von Dehn G, von Dehn O, Volker W, Langer C, Weinbauer GF, Behre HM, Nieschlag E, Assmann G, von Eckardstein A 2001 Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 33:110–114[CrossRef][Medline]
134. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P 1985 Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57:65–73[CrossRef][Medline]
135. Paigen B, Holmes PA, Mitchell D, Albee D 1987 Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis 64:215–221[CrossRef][Medline]
136. Napoli C, de Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, Palinski W 2002 Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 105:1360–1367[Abstract/Free Full Text]
137. Wang X, Paigen B 2002 Comparative genetics of atherosclerosis and restenosis: exploration with mouse models. Arterioscler Thromb Vasc Biol 22:884–886[Free Full Text]
138. Harmon KJ, Couper LL, Lindner V 2000 Strain-dependent vascular remodeling phenotypes in inbred mice. Am J Pathol 156:1741–1748[Abstract/Free Full Text]
139. Kuhel DG, Zhu B, Witte DP, Hui DY 2002 Distinction in genetic determinants for injury-induced neointimal hyperplasia and diet-induced atherosclerosis in inbred mice. Arterioscler Thromb Vasc Biol 22:955–960[Abstract/Free Full Text]
140. Ruygrok PN, Webster MW, de Valk V, van Es GA, Ormiston JA, Morel MA, Serruys PW 2001 Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. Circulation 104:2289–2294[Abstract/Free Full Text]
141. Larsen BA, Nordestgaard B, Stender S, Kjeldsen K 1993 Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99:79–86[CrossRef][Medline]
142. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, Benda N, Schmahl FW, Haasis R, Hanke H 1997 Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17:2192–2199[Abstract/Free Full Text]
143. Alexandersen P, Haarbo J, Bryjalsen I, Lawetz H, Christiansen C 1999 Natural androgens inhibit male atherosclerosis. A study in castrated, cholesterol-fed rabbits. Circ Res 84:813–819[Abstract/Free Full Text]
144. Gordon GB, Bush DE, Weisman HF 1988 Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 82:712–720
145. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN 1989 Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 9:159–166[Abstract/Free Full Text]
146. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML 1993 Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261–269[Abstract/Free Full Text]
147. Fogelberg M, Bjorkhem I, Diczfalusy U, Henriksson P 1990 Stanozolol and experimental atherosclerosis: atherosclerotic development and blood lipids during anabolic steroid therapy of New Zealand white rabbits. Scand J Clin Lab Invest 50:693–696[Medline]
148. Obasanjo IO, Clarkson TB, Weaver DS 1996 Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism 45:463–468[CrossRef][Medline]
149. Adams MR, Williams JK, Kaplan JR 1995 Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15:562–570[Abstract/Free Full Text]
150. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ 1996 Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93:10022–10027[Abstract/Free Full Text]
151. Elhage R, Bayard F, Holvoet P, Duverger N, Fievet C, Arnal JF 1997 Prevention of fatty streak formation of 17ß-estradiol is not mediated by the production of nitric oxide in apolipoprotein-E deficient mice. Circulation 96:3048–3052[Abstract/Free Full Text]
152. Elhage R, Arnal JF, Pieraggi MT, Duverger N, Fievet C, Faye JC, Bayard F 1997 17ß-Estradiol prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 17:2679–2684[Abstract/Free Full Text]
153. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT 2002 Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 87:5290–5296[Abstract/Free Full Text]
154. Lin AL, Schultz JJ, Brenner RM, Shain SA 1990 Sexual dimorphism characterizes baboon myocardial androgen receptors but not myocardial estrogen and progesterone receptors. J Steroid Biochem Mol Biol 37:85–95[CrossRef][Medline]
155. Lin AL, Gonzalez Jr R, Shain SA 1985 Androgen directs apparent cytoplasmic and nuclear distribution of rat cardiovascular androgen receptors. Arteriosclerosis 5:659–667[Abstract/Free Full Text]
156. Lin AL, Shain SA 1986 Sexual dimorphism characterizes steroid hormone modulation of rat aortic steroid hormone receptors. Endocrinology 119:296–302[Abstract/Free Full Text]
157. Lin AL, Gonzalez Jr R, Carey KD, Shain SA 1987 Gender and baboon aortic steroid hormone receptors. Arteriosclerosis 7: 248–255
158. Tamaya T, Misao R, Nakagawa M, Itoh T, Wada K, Fujimoto J, Imai A 1993 Estrogen and androgen receptors in aorta of the rabbit and regulation by estrogen and androgen. Res Commun Chem Pathol Pharmacol 82:3–11[Medline]
159. Knauthe R, Diel P, Hegele-Hartung C, Engelhaupt A, Fritzemeier KH 1996 Sexual dimorphism of steroid hormone receptor messenger ribonucleic acid expression and hormonal regulation in rat vascular tissue. Endocrinology 137:3220–3227[Abstract]
160. Higashiura K, Mathur RS, Halushka PV 1997 Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smooth-muscle cells. J Cardiovasc Pharmacol 29:311–315[CrossRef][Medline]
161. McCrohon JA, Death AK, Nakhla S, Jessup W, Handelsman DJ, Stanley KK, Celermajer DS 2000 Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 101:224–226[Abstract/Free Full Text]
162. Cutolo M, Accardo S, Villaggio B, Barone A, Sulli A, Coviello DA, Carabbio C, Felli L, Miceli D, Farruggio R, Carruba G, Castagnetta L 1996 Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. J Clin Endocrinol Metab 81:820–827[Abstract]
163. Death AK, McGrath KCY, Gaus K, Williams P, Handelsman DJ, Celermajer DS, Testosterone signalling through surface receptors in human endothelial cells: potential implications for nongenomic effects of testosterone on vessel walls (abstract). Program of the 51st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Adelaide, Australia, 2003 (Abstract)
164. Tindall DJ 2000 Androgen receptors in prostate and skeletal muscle. Mayo Clin Proc 75(Suppl):S26–S30; discussion S30–S31
165. Hanke H, Lenz C, Hess B, Spindler KD, Weidemann W 2001 Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103:1382–1385[Abstract/Free Full Text]
166. Libby P 2001 Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365–372[Free Full Text]
167. Ross R 1999 Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126[Free Full Text]
168. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS 1999 Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 99:2317–2322[Abstract/Free Full Text]
169. McGrath KCY, Sader MS, Nakhla S, Jessup W, Handelsman DJ, Celermajer DS, Death AK, Androgens up-regulate VCAM-1 in a gender specific manner via a NFß-dependent pathway in human endothelial cells. Program of the 51st Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand, Adelaide, Australia, 2003 (Abstract)
170. Zhang X, Wang LY, Jiang TY, Zhang HP, Dou Y, Zhao JH, Zhao H, Qiao ZD, Qiao JT 2002 Effects of testosterone and 17-ß-estradiol on TNF--induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci 71:15–29[CrossRef][Medline]
171. Hatakeyama H, Nishizawa M, Nakagawa A, Nakano S, Kigoshi T, Uchida K 2002 Testosterone inhibits tumor necrosis factor--induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Lett 530:129–132[CrossRef][Medline]
172. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L 2002 Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 99:4055–4060[Abstract/Free Full Text]
173. Bombeli T, Schwartz BR, Harlan JM 1999 Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 93:3831–3838[Abstract/Free Full Text]
174. Ling S, Dai A, Williams MR, Myles K, Dilley RJ, Komesaroff PA, Sudhir K 2002 Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology 143:1119–1125[Abstract/Free Full Text]
175. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R 1996 Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 148:969–976[Abstract]
176. Akishita M, Ouchi Y, Miyoshi H, Kozaki K, Inoue S, Ishikawa M, Eto M, Toba K, Orimo H 1997 Estrogen inhibits cuff-induced intimal thickening of rat femoral artery: effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130:1–10[CrossRef][Medline]
177. Chen SJ, Li H, Durand J, Oparil S, Chen YF 1996 Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93:577–584[Abstract/Free Full Text]
178. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, von Dehn G, Jansen H, Assmann G, von Eckardstein A 2002 Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 296:1051–1057[CrossRef][Medline]
179. Fluiter K, van der Westhuijzen DR, van Berkel TJ 1998 In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J Biol Chem 273:8434–8438[Abstract/Free Full Text]
180. Friedl R, Brunner M, Moeslinger T, Spieckermann PG 2000 Testosterone inhibits expression of inducible nitric oxide synthase in murine macrophages. Life Sci 68:417–429[CrossRef][Medline]
181. Benten PM, Lieberherr M, Stamm O, Werehlke C, Guo Z, Wunderlich F 1999 Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. Mol Biol Cell 10:393–397[Abstract/Free Full Text]
182. Guo Z, Benten PM, Krucken J, Wunderlich F 2002 Nongenomic testosterone calcium signaling-genotropic actions in androgen receptor-free macrophages. J Biol Chem 277:29600–29607[Abstract/Free Full Text]
183. Rubio-Gayosso I, Garcia-Ramirez O, Gutierrez-Serdan R, Guevara-Balcazar M, Munoz-Garcia O, Morato-Cartajena T, Zamora-Garza M, Ceballos-Reyes G 2002 Testosterone inhibits bradykinin-induced intracellular calcium kinetics in rat aortic endothelial cells in culture. Steroids 67:393–397[CrossRef][Medline]
184. Lieberherr M, Grosse B 1994 Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem 269:7217–7223[Abstract/Free Full Text]
185. Turner HH 1950 The clinical use of testosterone. Springfield, IL: Charles C. Thomas; 17
186. Costarella CE, Stallone JN, Rutecki GW, Whittier FC 1996 Testosterone causes direct relaxation of rat thoracic aorta. J Pharmacol Exp Ther 277:34–39[Abstract/Free Full Text]
187. Crews JK, Khalil RA 1999 Gender-specific inhibition of Ca²⁺ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol 26:707–715[CrossRef][Medline]
188. Perusquia M, Villalon CM 1999 Possible role of Ca²⁺ channels in the vasodilating effect of 5ß-dihydrotestosterone in rat aorta. Eur J Pharmacol 371:169–178[CrossRef][Medline]
189. Ding AQ, Stallone JN 2001 Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K⁺ channel activation. J Appl Physiol 91:2742–2750[Abstract/Free Full Text]
190. Tep-areenan P, Kendall DA, Randall MD 2002 Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 135:735–740[CrossRef][Medline]
191. Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH 2003 Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol 148:111–120[Abstract]
192. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P 1995 Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91:1154–1160[Abstract/Free Full Text]
193. Crews JK, Khalil RA 1999 Antagonistic effects of 17ß-estradiol, progesterone, and testosterone on Ca²⁺ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19:1034–1040[Abstract/Free Full Text]
194. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ 2001 Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281:H1720–H1727
195. Schror K, Morinelli TA, Masuda A, Matsuda K, Mathur RS, Halushka PV 1994 Testosterone treatment enhances thromboxane A2 mimetic induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest 24(Suppl 1):50–52
196. Farrukh IS, Peng W, Orlinska U, Hoidal JR 1998 Effect of dehydroepiandrosterone on hypoxic pulmonary vasoconstriction: a Ca²⁺-activated K⁺-channel opener. Am J Physiol 274:L186–L195
197. Chou TM, Sudhir K, Hutchinson SJ, Ko E, Amidon TM, Collins P, Chatterjee K 1996 Testosterone induces dilatation of canine coronary conductance and resistance arteries in vivo. Circulation 94:2614–2619[Abstract/Free Full Text]
198. Stallone JN, Salisbury RL, Fulton CT 2001 Androgen-receptor defect abolishes sex differences in nitric oxide and reactivity to vasopressin in rat aorta. J Appl Physiol 91:2602–2610[Abstract/Free Full Text]
199. Ceballos G, Figueroa L, Rubio I, Gallo G, Garcia A, Martinez A, Yanez R, Perez J, Morato T, Chamorro G 1999 Acute and nongenomic effects of testosterone on isolated and perfused rat heart. J Cardiovasc Pharmacol 33:691–697[CrossRef][Medline]
200. Figueroa-Valverde L, Luna H, Castillo-Henkel C, Munoz-Garcia O, Morato-Cartagena T, Ceballos-Reyes G 2002 Synthesis and evaluation of the cardiovascular effects of two, membrane impermeant, macromolecular complexes of dextran-testosterone. Steroids 67:611–619[CrossRef][Medline]
201. Teoh H, Quan A, Man RY 2000 Acute impairment of relaxation by low levels of testosterone in porcine coronary arteries. Cardiovasc Res 45:1010–1018[Abstract/Free Full Text]
202. Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS 2002 Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol 39: 814–823
203. Murphy JG, Khalil RA 1999 Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17ß-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291:44–52[Abstract/Free Full Text]
204. English KM, Jones RD, Jones TH, Morice AH, Channer KS 2002 Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 25:455–458[Medline]
205. Peng W, Hoidal JR, Farrukh IS 1999 Role of a novel KCa opener in regulating K⁺ channels of hypoxic human pulmonary vascular cells. Am J Respir Cell Mol Biol 20:737–745[Abstract/Free Full Text]
206. Molinari C, Battaglia A, Grossini E, Mary DA, Vassanelli C, Vacca G 2002 The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol 543:365–372[Abstract/Free Full Text]
207. Ferrer M, Encabo A, Marin J, Balfagon G 1994 Treatment with the anabolic steroid, nandrolone, reduces vasoconstrictor responses in rabbit arteries. Eur J Pharmacol 258:103–110[CrossRef][Medline]
208. English KM, Jones RD, Jones TH, Morice AH, Channer KS 2001 Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 33:645–652[CrossRef][Medline]
209. English KM, Jones RD, Jones TH, Morice AH, Channer KS 2000 Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodilatory action of testosterone. Clin Sci (Lond) 99:77–82[Medline]
210. Bhargava KP, Dhawan KN, Saxena RC 1967 Enhancement of noradrenaline pressor responses in testosterone-treated cats. Br J Pharmacol 31:26–31[Medline]
211. Greenberg S, Heitz DC, Long JP 1973 Testosterone-induced depression of adrenergic activity in the perfused canine hindlimb. Proc Soc Exp Biol Med 142:883–888[CrossRef][Medline]
212. Greenberg S, George WR, Kadowitz PJ, Wilson WR 1974 Androgen-induced enhancement of vascular reactivity. Can J Physiol Pharmacol 52:14–22[Medline]
213. Ferrer M, Encabo A, Marin J, Balfagon G 1994 Chronic treatment with the anabolic steroid, nandrolone, inhibits vasodilator responses in rabbit aorta. Eur J Pharmacol 252:233–241[CrossRef][Medline]
214. Sader MA, Celermajer DS 2002 Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovasc Res 53:597–604[Free Full Text]
215. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P 1986 Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046–1051[Abstract]
216. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE 1992 Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115[CrossRef][Medline]
217. Raitakari OT, Celermajer DS 2000 Flow-mediated dilatation. Br J Clin Pharmacol 50:397–404[CrossRef][Medline]
218. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y 1995 Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92:3431–3435[Abstract/Free Full Text]
219. Simons LA, von Konigsmark M, Simons J, Stocker R, Celermajer DS 1999 Vitamin E ingestion does not improve arterial endothelial dysfunction in older adults. Atherosclerosis 143:193–199[CrossRef][Medline]
220. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE 1994 Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24:471–476[Abstract]
221. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS 1997 Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 17:2004–2009[Abstract/Free Full Text]
222. Zitzmann M, Brune M, Nieschlag E 2002 Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 87:5030–5037[Abstract/Free Full Text]
223. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, Kirschenlohr HL 2001 Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 103:1497–502[Abstract/Free Full Text]
224. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P 2000 Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 85:269–272[CrossRef][Medline]
225. Kang SM, Jang Y, Kim JY, Chung N, Cho SY, Chae JS, Lee JH 2002 Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89:862–864[CrossRef][Medline]
226. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS 2001 Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol 37:224–230[Abstract/Free Full Text]
227. Ebenbichler CF, Sturm W, Ganzer H, Bodner J, Mangweth B, Ritsch A, Sandhofer A, Lechleitner M, Foger B, Patsch JR 2001 Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 158:483–490[CrossRef][Medline]
228. Kenny AM, Prestwood KM, Gruman CA, Fabregas G, Biskup B, Mansoor G 2002 Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 57:M460–M465
229. Liu PY, Wishart SM, Celermajer DS, Jimenez M, Pierro ID, Conway AJ, Handelsman DJ 2003 Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol 148:55–66[Abstract]
230. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ 2001 A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078–4088[Abstract/Free Full Text]
231. McCrohon JA, Walters WA, Robinson JTC, McCredie RJ, Turner L, Adams MR, Handelsman DJ, Celermajer DS 1997 Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 29:1432–1436[Abstract]
232. New G, Timmins KL, Duffy SJ, Tran BT, O’Brien RC, Harper RW, Meredith IT 1997 Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 29:1437–1444[Abstract]
233. New G, Duffy SJ, Harper RW, Meredith IT 2000 Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males. Clin Exp Pharmacol Physiol 27:25–33[CrossRef][Medline]
234. Komesaroff PA, Fullerton M, Esler MD, Dart A, Jennings G, Sudhir K 2001 Low-dose estrogen supplementation improves vascular function in hypogonadal men. Hypertension 38:1011–1016[Abstract/Free Full Text]
235. Sader MA, McCredie RJ, Griffiths KA, Wishart SM, Handelsman DJ, Celermajer DS 2001 Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clin Endocrinol (Oxf) 54:175–181[CrossRef][Medline]
236. New G, Duffy SJ, Berry KL, Harper RW, Meredith IT 1999 Acute administration of 17ß-oestradiol does not improve endothelium-dependent vasodilatation in young men. Clin Sci (Lond) 97:225–232[Medline]
237. Sudhir K, Chou TM, Messina LM, Hutchison SJ, Korach KS, Chatterjee K, Rubanyi GM 1997 Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349:1146–1147[CrossRef][Medline]
238. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS 1998 Vascular reactivity is impaired in genetic females taking high dose androgens. J Am Coll Cardiol 32:1331–1335[Abstract/Free Full Text]
239. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR 2001 Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 86:158–161[Abstract/Free Full Text]
240. Alexandersen P, Haarbo J, Christiansen C 1996 The relationship of natural androgens to coronary heart disease in male: a review. Atherosclerosis 125:1–13[CrossRef][Medline]
241. English KM, Steeds R, Jones TH, Channer KS 1997 Testosterone and coronary heart disease: is there a link? QJM 90:787–791[Medline]
242. Wu FCW, von Eckardstein A 2002 Androgen and coronary artery disease. In: McLachlan RI, ed. Male reproductive endocrinology, Endotext.com, Chap. 16 (web version of Endocrinology, 4th ed.). www.endotext.org
243. Barrett-Connor EL 1995 Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab 21:156–161
244. Barrett-Connor E 1996 Testosterone, HDL-cholesterol and cardiovascular disease. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C, eds. Pharmacology, biology, and clinical applications of androgens: current status and future prospects. New York: Wiley-Liss; 215–223
245. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS 2000 Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 21:890–894[Abstract/Free Full Text]
246. Hak AE, Witteman JC, De Jong FH, Geerlings MI, Hofman A, Pols HA 2002 Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87:3632–3639[Abstract/Free Full Text]
247. Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M 1985 Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 60:444–450[Abstract/Free Full Text]
248. Semple CG, Gray CE, Beastall GH 1987 Male hypogonadism: a non-specific consequence of illness. Q J Med 64:601–607[Medline]
249. Gray A, Feldman HA, McKinlay JB, Longcope C 1991 Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73:1016–1025[Abstract/Free Full Text]
250. Handelsman DJ 1997 Testicular dysfunction in systemic diseases. In: Nieschlag E, Behre HM, eds. Andrology: male reproductive health and dysfunction. Berlin: Springer-Verlag; 227–237
251. Barrett-Connor E, Khaw KT 1988 Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539–545[Abstract/Free Full Text]
252. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB 2001 Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 153:79–89[Abstract/Free Full Text]
253. Barrett-Connor E, Khaw KT, Yen SS 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519–1524[Abstract]
254. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM 1990 Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 11:460–470[Abstract/Free Full Text]
255. LaCroix AZ, Yano K, Reed DM 1992 Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 86:1529–1535[Abstract/Free Full Text]
256. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ 1994 Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol 140:870–875[Abstract/Free Full Text]
257. Barrett-Connor E, Goodman-Gruen D 1995 The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci 774:259–270[Medline]
258. Meikle AW, Dorchuck RW, Araneo BA, Stringham JD, Evans TG, Spruance SL, Daynes RA 1992 The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 42:293–304[CrossRef][Medline]
259. Okabe T, Haji M, Takayanagi R, Adachi M, Imasaki K, Kurimoto F, Watanabe T, Nawata H 1995 Up-regulation of high-affinity dehydroepiandrosterone binding activity by dehydroepiandrosterone in activated human T lymphocytes. J Clin Endocrinol Metab 80:2993–2996[Abstract/Free Full Text]
260. Tsuji K, Furutama D, Tagami M, Ohsawa N 1999 Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy. Life Sci 65:17–26[CrossRef][Medline]
261. Willson TM, Moore JT 2002 Genomics vs. orphan nuclear receptors–a half-time report. Mol Endocrinol 16:1135–1144[Abstract/Free Full Text]
262. Baulieu EE, Robel P, Schumacher M 2001 Neurosteroids: beginning of the story. Int Rev Neurobiol 46:1–32
263. Gupte SA, Li KX, Okada T, Sato K, Oka M 2002 Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium channels. J Pharmacol Exp Ther 301:299–305[Abstract/Free Full Text]
264. Svec F, Porter JR 1998 The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc Soc Exp Biol Med 218:174–191[CrossRef][Medline]
265. Jansson JH, Nilsson TK, Johnson O 1998 von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80:334–337[Abstract/Free Full Text]
266. Moriyama Y, Yasue H, Yoshimura M, Mizuno Y, Nishiyama K, Tsunoda R, Kawano H, Kugiyama K, Ogawa H, Saito Y, Nakao K 2000 The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab 85:1834–1840[Abstract/Free Full Text]
267. Walker TC 1942 Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. J Clin Endocrinol 2:560–568[Abstract/Free Full Text]
268. Sigler LH, Tulgan J 1943 Treatment of angina pectoris by testosterone propionate. NY State J Med 43:1424–1428
269. Lesser MA 1946 Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol Metab 6:549–557[Abstract/Free Full Text]
270. Kochakian CD 1976 Anabolic-androgenic steroids. Berlin: Springer-Verlag
271. Jaffe MD 1977 Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 39:1217–1222[Abstract/Free Full Text]
272. Wu S, Weng X 1993 Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J (Engl) 106:415–418[Medline]
273. Wu S, Weng X 1992 Therapeutic effects of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients. Chin Med Sci J 7:137–141[Medline]
274. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS 2000 Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102:1906–1911[Abstract/Free Full Text]
275. Webb CM, Adamson DL, de Zeigler D, Collins P 1999 Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83:437–439; A9[CrossRef][Medline]
276. Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL 1999 Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99:1666–1670[Abstract/Free Full Text]
277. Thompson PD, Ahlberg AW, Moyna NM, Duncan B, Ferraro-Borgida M, White CM, McGill CC, Heller GV 2002 Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease. Am Heart J 143:249–256[CrossRef][Medline]
278. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P 1999 Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690–1696[Abstract/Free Full Text]
279. Reckelhoff JF 2001 Gender differences in the regulation of blood pressure. Hypertension 37:1199–1208[Abstract/Free Full Text]
280. Dubey RK, Oparil S, Imthurn B, Jackson EK 2002 Sex hormones and hypertension. Cardiovasc Res 53:688–708[Abstract/Free Full Text]
281. Staessen J, Fagard R, Lijnen P, Thijs L, van Hoof R, Amery A 1990 Reference values for ambulatory blood pressure: a meta-analysis. J Hypertens Suppl 8:S57–S64
282. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D 1995 Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25:305–313[Abstract/Free Full Text]
283. Dockery F, Rajkumar C, Agarwal S, Waxman J, Bulpitt CJ 2000 Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressure. J Hum Hypertens 14:395–397[CrossRef][Medline]
284. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267[Abstract/Free Full Text]
285. Henriksson P, Linde B 1994 Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma. Urol Int 53:74–78[CrossRef][Medline]
286. Khaw KT, Barrett-Connor E 1988 Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens 6:329–332[Medline]
287. Gray A, Berlin JA, McKinlay JB, Longcope C 1991 An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 44:671–684[CrossRef][Medline]
288. Fogari R, Zoppi A, Preti P, Rinaldi A, Marasi G, Vanasia A, Mugellini A 2002 Sexual activity and plasma testosterone levels in hypertensive males. Am J Hypertens 15:217–221[CrossRef][Medline]
289. Hughes GS, Mathur RS, Margolius HS 1989 Sex steroid hormones are altered in essential hypertension. J Hypertens 7:181–187[Medline]
290. Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE 1993 Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 11:699–702[CrossRef][Medline]
291. Jaffe A, Chen Y, Kisch ES, Fischel B, Alon M, Stern N 1996 Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 28:859–862[Abstract/Free Full Text]
292. Rosen RC 1997 Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1:47–51[Medline]
293. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P 1999 The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 12:271–275[CrossRef][Medline]
294. Suzuki H, Tominaga T, Kumagai H, Saruta T 1988 Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens 6:S649–S651
295. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A 2002 Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 58:177–180[CrossRef][Medline]
296. Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Trimarchi F, Benvenga S 1999 Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 22:385–392[CrossRef][Medline]
297. Reckelhoff JF, Zhang H, Srivastava K, Granger JP 1999 Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. Hypertension 34:920–923[Abstract/Free Full Text]
298. Cambotti LJ, Cole FE, Gerall AA, Frohlich ED, MacPhee AA 1984 Neonatal gonadal hormones and blood pressure in the spontaneously hypertensive rat. Am J Physiol 247:E258–E264
299. Reckelhoff JF, Zhang H, Srivastava K 2000 Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension 35:480–483[Abstract/Free Full Text]
300. Jin B, Beilin J, Zajac J, Handelsman DJ 2000 Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men. J Androl 21:91–98[Abstract]
301. Khalid M, Ilhami N, Giudicelli Y, Dausse JP 2002 Testosterone dependence of salt-induced hypertension in Sabra rats and role of renal (2)-adrenoceptor subtypes. J Pharmacol Exp Ther 300:43–49[Abstract/Free Full Text]
302. Ely D, Caplea A, Dunphy G, Daneshvar H, Turner M, Milsted A, Takiyyudin M 1997 Spontaneously hypertensive rat Y chromosome increases indexes of sympathetic nervous system activity. Hypertension 29:613–618[Abstract/Free Full Text]
303. Schmalbach NL, Kutscher CL 1976 Testosterone and the sex difference in blood pressure in mice. Pharmacol Biochem Behav 4:339–341[CrossRef][Medline]
304. Lim YK, Retnam L, Bhagavath B, Sethi SK, bin Ali A, Lim SK 2002 Gonadal effects on plasma ACE activity in mice. Atherosclerosis 160:311–316[CrossRef][Medline]
305. Freshour JR, Chase SE, Vikstrom KL 2002 Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice. Am J Physiol Heart Circ Physiol 283:H1997–H2003
306. Cvetkovic B, Sigmund CD 2000 Understanding hypertension through genetic manipulation in mice. Kidney Int 57:863–874[CrossRef][Medline]
307. Sigmund CD 2001 Genetic manipulation of the renin-angiotensin system: targeted expression of the renin-angiotensin system in the kidney. Am J Hypertens 14:33S–37S
308. Hayward CS, Kelly RP, Collins P 2000 The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 46:28–49[Free Full Text]
309. Hayward CS, Webb CM, Collins P 2001 Effect of sex hormones on cardiac mass. Lancet 357:1354–1356[CrossRef][Medline]
310. Gardner JD, Brower GL, Janicki JS 2002 Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 8:101–107[CrossRef][Medline]
311. Nahrendorf M, Frantz S, Hu K, von zur Muhlen C, Tomaszewski M, Scheuermann H, Kaiser R, Jazbutyte V, Beer S, Bauer W, Neubauer S, Ertl G, Allolio B, Callies F 2003 Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res 57:370–378[Abstract/Free Full Text]
312. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP 2003 Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 284:H1560–H1569
313. Thum T, Borlak J 2002 Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537–1549[Abstract/Free Full Text]
314. Takeishi Y, Walsh RA 2001 Cardiac hypertrophy and failure: lessons learned from genetically engineered mice. Acta Physiol Scand 173:103–111[CrossRef][Medline]
315. Brouillette J, Trepanier-Boulay V, Fiset C 2003 Effect of androgen deficiency on mouse ventricular repolarization. J Physiol 546:403–413[Abstract/Free Full Text]
316. Noirhomme P, Jacquet L, Underwood M, El Khoury G, Goenen M, Dion R 1999 The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure. Eur J Cardiothorac Surg 16:63–67[Abstract/Free Full Text]
317. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, Tsagalou EP, Nanas JN 2003 Hormonal profile in patients with congestive heart failure. Int J Cardiol 87:179–183[CrossRef][Medline]
318. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, Poole-Wilson PA, Coats AJ 1997 Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526–534[Abstract/Free Full Text]
319. Kiilavuori K, Naveri H, Leinonen H, Harkonen M 1999 The effect of physical training on hormonal status and exertional hormonal response in patients with chronic congestive heart failure. Eur Heart J 20:456–464[Abstract/Free Full Text]
320. Handelsman DJ, Dong Q 1992 Ontogenic regression: a model of stress and reproduction. In: Sheppard K, Boublik JH, Funder JW, eds. Stress and reproduction. New York: Raven Press; 333–345
321. Pugh PJ, Jones RD, West JN, Channer KS, Jones TH, Testosterone therapy for men with chronic congestive heart failure. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 144 (Abstract OR59-4)
322. Coats AJ 2002 Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. Int J Cardiol 85:133–139[CrossRef][Medline]
323. Young W, Gofman JW, Tandy R, Malamud N, Waters ESG 1960 The quantification of atherosclerosis. III. The extent of correlation of degrees of atherosclerosis within and between coronary and cerebral vascular beds. Am J Cardiol 6:300–308[CrossRef]
324. Solberg LA, Strong JP 1983 Risk factors and atherosclerotic lesions. A review of autopsy studies. Arteriosclerosis 3:187–198[Abstract/Free Full Text]
325. Sorensen KE, Kristensen IB, Celermajer DS 1997 Atherosclerosis in the human brachial artery. J Am Coll Cardiol 29:318–322[Abstract]
326. Thubrikar MJ, Robicsek F 1995 Pressure-induced arterial wall stress and atherosclerosis. Ann Thorac Surg 59:1594–1603[Abstract/Free Full Text]
327. Drouet L 2002 Atherothrombosis as a systemic disease. Cerebrovasc Dis 13(Suppl 1):1–6
328. Simons PC, Algra A, Bots ML, Banga JD, Grobbee DE, van der Graaf Y 1999 Common carotid intima-media thickness in patients with peripheral arterial disease or abdominal aortic aneurysm: the SMART study. Second Manifestations of ARTerial disease. Atherosclerosis 146:243–248[CrossRef][Medline]
329. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M 1995 Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 26:361–367[Abstract/Free Full Text]
330. Sudlow CL, Warlow CP 1997 Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 28:491–499[Abstract/Free Full Text]
331. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA 1997 American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 28:1507–1517[Free Full Text]
332. Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO 1996 Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 27:373–380
333. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA 2001 Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke 32:1732–1738[Abstract/Free Full Text]
334. Jeppesen LL, Jorgensen HS, Nakayama H, Raaschou HO, Skyhoj T, Winther K 1996 Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 16:749–754[Abstract/Free Full Text]
335. Elwan O, Abdallah M, Issa I, Taher Y, el-Tamawy M 1990 Hormonal changes in cerebral infarction in the young and elderly. J Neurol Sci 98:235–243[CrossRef][Medline]
336. Dash RJ, Sethi BK, Nalini K, Singh S 1991 Circulating testosterone in pure motor stroke. Funct Neurol 6:29–34[Medline]
337. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE 2003 Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157:25–31[Abstract/Free Full Text]
338. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK 1999 Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22[Abstract/Free Full Text]
339. Friedl KE 1993 Effects of anabolic steroids on physical health. In: Yesalis CE, ed. Anabolic steroids in sports and exercise. Champaign, IL: Human Kinetics Publishers; 107–150
340. Akhter J, Hyder S, Ahmed M 1994 Cerebrovascular accident associated with anabolic steroid use in a young man. Neurology 44:2405–2406[Free Full Text]
341. Jaillard AS, Hommel M, Mallaret M 1994 Venous sinus thrombosis associated with androgens in a healthy young man. Stroke 25:212–213[Abstract]
342. Palfi S, Ungurean A, Vecsei L 1997 Basilar artery occlusion associated with anabolic steroid abuse in a 17-year-old bodybuilder. Eur Neurol 37:190–191[CrossRef][Medline]
343. Ebo DG, Bracke PG, De Clerck LS, Francx LM, Stevens WJ 1997 Anticardiolipin (aCL) antibodies in a patient with Behcet’s syndrome with vena cava inferior thrombosis. Clin Rheumatol 16:96–98[CrossRef][Medline]
344. Lisiewicz J, Fijalkowski P, Sankowski J 1999 [Ischemic cerebral stroke and anabolic steroids (case report)]. Neurol Neurochir Pol 32(Suppl 6):137–139
345. Nagelberg SB, Laue L, Loriaux DL, Liu L, Sherins RJ 1986 Cerebrovascular accident associated with testosterone therapy in a 21-year-old hypogonadal man. N Engl J Med 314:649–650[Medline]
346. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L, Vignali M 2001 Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril 76:235–240[CrossRef][Medline]
347. Geary GG, Krause DN, Duckles SP 2000 Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am J Physiol Heart Circ Physiol 279:H610–H618
348. Yamori Y, Horie R, Sato M, Ohta K 1976 Proceedings: prophylactic trials for stroke in stroke-prone SHR: effect of sex hormones. Jpn Heart J 17:404–406[Medline]
349. Green PS, Simpkins JW 2000 Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18:347–358[CrossRef][Medline]
350. Wise PM 2002 Estrogens and neuroprotection. Trends Endocrinol Metab 13:229–230[CrossRef][Medline]
351. Toung TJ, Traystman RJ, Hurn PD 1998 Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 29:1666–1670[Abstract/Free Full Text]
352. Yu WH, Yu MC 1983 Acceleration of the regeneration of the crushed hypoglossal nerve by testosterone. Exp Neurol 80:349–360[CrossRef][Medline]
353. Kujawa KA, Tanzer L, Jones KJ 1995 Inhibition of the accelerative effects of testosterone on hamster facial nerve regeneration by the antiandrogen flutamide. Exp Neurol 133:138–143[CrossRef][Medline]
354. Hammond J, Le Q, Goodyer C, Gelfand M, Trifiro M, LeBlanc A 2001 Testosterone-mediated neuroprotection through the androgen receptor in human primary neurons. J Neurochem 77:1319–1326[CrossRef][Medline]
355. Ahlbom E, Prins GS, Ceccatelli S 2001 Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res 892:255–262[CrossRef][Medline]
356. Jones KJ, Brown TJ, Damaser M 2001 Neuroprotective effects of gonadal steroids on regenerating peripheral motoneurons. Brain Res Brain Res Rev 37:372–382[CrossRef][Medline]
357. Azcoitia I, Sierra A, Veiga S, Honda S, Harada N, Garcia-Segura LM 2001 Brain aromatase is neuroprotective. J Neurobiol 47:318–329[CrossRef][Medline]
358. Green PS, Yang SH, Simpkins JW 2000 Neuroprotective effects of phenolic A ring oestrogens. Novartis Found Symp 230:202–213; discussion, 213–220[Medline]
359. Hawk T, Zhang YQ, Rajakumar G, Day AL, Simpkins JW 1998 Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res 796:296–298[CrossRef][Medline]
360. Yang SH, Perez E, Cutright J, Liu R, He Z, Day AL, Simpkins JW 2002 Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model. J Appl Physiol 92:195–201[Abstract/Free Full Text]
361. Dong Q, Hawker F, McWilliam D, Bangah M, Burger H, Handelsman DJ 1992 Circulating inhibin and testosterone levels in men with critical illness. Clin Endocrinol (Oxf) 36:399–404[Medline]
362. Ba ZF, Wang P, Koo DJ, Ornan DA, Bland KI, Chaudry IH 2001 Attenuation of vascular endothelial dysfunction by testosterone receptor blockade after trauma and hemorrhagic shock. Arch Surg 136:1158–1163[Abstract/Free Full Text]
363. Dormandy JA, Rutherford RB 2000 Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 31:S1–S296
364. Hiatt WR 2001 Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608–1621[Free Full Text]
365. McDermott MM, Mehta S, Ahn H, Greenland P 1997 Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 12:209–215[CrossRef][Medline]
366. Clark AL, Byrne JC, Nasser A, McGroarty E, Kennedy JA 1999 Cholesterol in peripheral vascular disease—a suitable case for treatment? QJM 92:219–222[Abstract/Free Full Text]
367. Norman PE, Semmens JB, Lawrence-Brown M, Holman CD 2000 The influence of gender on outcome following peripheral vascular surgery: a review. Cardiovasc Surg 8:111–115[CrossRef][Medline]
368. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE 1998 Peripheral arterial disease in the elderly: the Rotterdam study. Arterioscler Thromb Vasc Biol 18:185–192[Abstract/Free Full Text]
369. Edwards EA, Hamilton JB, Duntley SQ 1939 Testosterone propionate as a therapeutic agent in patients with organic disease of the peripheral vessels. Preliminary report. N Engl J Med 220:865
370. Hamilton JB 1937 Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 21:649–654[Abstract/Free Full Text]
371. Hentzer E, Madsen PC 1967 Testosterone in the treatment of arterial insufficiency of the lower limbs. Scand J Clin Lab Invest 99:198–206
372. Dohn K, Hvidt V, Nielsen J, Palm L 1968 Testosterone therapy in obliterating arterial lesions in the lower limbs. Angiology 19:342–350
373. Genster HG, Oram V 1971 Medical treatment of arterial insufficiency in the lower limbs. Ugeskr Laeger 133:244–246[Medline]
374. Albrechtsen O, Barfod B, Barfod E, Laursen NP, Nordentoft B, Yde H 1972 Hormonal treatment of arterial insufficiency in the lower extremities. Dan Med Bull 19:157–159[Medline]
375. Price JF, Leng GC 2002 Steroid sex hormones for lower limb atherosclerosis (Cochrane review). Cochrane database of systematic reviews. 4th ed. Oxford, UK: Update Software; 4
376. Simonsen U, Garcia-Sacristan A, Prieto D 2002 Penile arteries and erection. J Vasc Res 39:283–303[CrossRef][Medline]
377. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ 1992 Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326:90–94[Abstract]
378. Gonzalez-Cadavid NF, Ignarro LJ, Rajfer J 1999 Nitric oxide and the cyclic GMP system in the penis. Mol Urol 3:51–59[Medline]
379. Archer SL 2002 Potassium channels and erectile dysfunction. Vascul Pharmacol 38:61–71[CrossRef][Medline]
380. Lue TF 2000 Erectile dysfunction. N Engl J Med 342:1802–1813[Free Full Text]
381. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA 1998 Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338:1397–1404[Abstract/Free Full Text]
382. Corbin JD, Francis SH, Webb DJ 2002 Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60:4–11[Medline]
383. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB 1994 Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61[Medline]
384. Sullivan ME, Keoghane SR, Miller MA 2001 Vascular risk factors and erectile dysfunction. BJU Int 87:838–845[CrossRef][Medline]
385. Azadzoi KM, Goldstein I 1992 Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 147:1675–1681[Medline]
386. Adams MR, Kaplan JR, Koritnik DR, Weaver DS, Bond MG 1984 Erectile failure in cynomolgus monkeys with atherosclerosis of the arteries supplying the penis. J Urol 131:571–573[Medline]
387. Thompson PD, Zimet R, Forbes WP, Zhang P 2002 Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 90:1314–1319[CrossRef][Medline]
388. Regensteiner JG, Ware Jr JE, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR 2002 Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50:1939–1946[CrossRef][Medline]
389. Virag R, Bouilly P, Frydman D 1985 Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1:181–184[Medline]
390. Michal V 1982 Arterial disease as a cause of impotence. Clin Endocrinol Metab 11:725–748[CrossRef][Medline]
391. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB 2000 Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 30:328–338[CrossRef][Medline]
392. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB 2000 Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 56:302–306[CrossRef][Medline]
393. Jackson G 1997 Simvastatin and impotence. Br Med J 315:31[Free Full Text]
394. Pedersen TR, Faergeman O 1999 Simvastatin seems unlikely to cause impotence. BMJ 318:192[Free Full Text]
395. Rizvi K, Hampson JP, Harvey JN 2002 Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19:95–98[Abstract/Free Full Text]
396. Bancroft J 1995 Are the effects of androgens on male sexuality noradrenergically mediated? Some consideration of the human. Neurosci Biobehav Rev 19:325–330[CrossRef][Medline]
397. Wilson JD 1999 The role of androgens in male gender role behavior. Endocr Rev 20:726–737[Abstract/Free Full Text]
398. Carani C, Granata AR, Bancroft J, Marrama P 1995 The effects of testosterone replacement on nocturnal penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 20:743–753[CrossRef][Medline]
399. Keast JR 2000 Effects of testosterone on pelvic autonomic pathways: progress and pitfalls. J Auton Nerv Syst 79:67–73[CrossRef][Medline]
400. Shabsigh R 1997 The effects of testosterone on the cavernous tissue and erectile function. World J Urol 15:21–26[CrossRef][Medline]
401. Melman A, Gingell JC 1999 The epidemiology and pathophysiology of erectile dysfunction. J Urol 161:5–11[CrossRef][Medline]
402. Schiavi RC, White D, Mandeli J, Levine AC 1997 Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav 26:231–241[CrossRef][Medline]
403. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP 1999 Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 43:658–665[Abstract/Free Full Text]
404. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F, De Lucia D, Giugliano D 2001 Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia 44:1155–1160[CrossRef][Medline]
405. Virag R 2002 Flow-dependent dilatation of the cavernous artery. A potential test of penile NO content. J Mal Vasc 27:214–217[Medline]

This article has been cited by other articles:

				L. Sacca Heart Failure as a Multiple Hormonal Deficiency Syndrome Circ Heart Fail, March 1, 2009; 2(2): 151 - 156. [Full Text] [PDF]

				L. Ruan, W. Chen, S. R. Srinivasan, M. Sun, H. Wang, A. Toprak, and G. S. Berenson Correlates of Common Carotid Artery Lumen Diameter in Black and White Younger Adults: The Bogalusa Heart Study Stroke, March 1, 2009; 40(3): 702 - 707. [Abstract] [Full Text] [PDF]

				L. McRobb, D. J. Handelsman, and A. K. Heather Androgen-Induced Progression of Arterial Calcification in Apolipoprotein E-Null Mice Is Uncoupled from Plaque Growth and Lipid Levels Endocrinology, February 1, 2009; 150(2): 841 - 848. [Abstract] [Full Text] [PDF]

				B. A. Inman, J. L. St. Sauver, D. J. Jacobson, M. E. McGree, A. Nehra, M. M. Lieber, V. L. Roger, and S. J. Jacobsen A Population-Based, Longitudinal Study of Erectile Dysfunction and Future Coronary Artery Disease Mayo Clin. Proc., February 1, 2009; 84(2): 108 - 113. [Abstract] [Full Text] [PDF]

				M. E. Reichelt, L. Willems, B. A. Hack, J. N. Peart, and J. P. Headrick Cardiac and coronary function in the Langendorff-perfused mouse heart model Exp Physiol, January 1, 2009; 94(1): 54 - 70. [Abstract] [Full Text] [PDF]

				A. Mancini, E. Leone, R. Festa, G. Grande, A. Silvestrini, L. de Marinis, A. Pontecorvi, G. Maira, G. P. Littarru, and E. Meucci Effects of Testosterone on Antioxidant Systems in Male Secondary Hypogonadism J Androl, November 1, 2008; 29(6): 622 - 629. [Abstract] [Full Text] [PDF]

				Y. Chen, F. Rao, J. L. Rodriguez-Flores, M. Mahata, M. M. Fung, M. Stridsberg, S. M. Vaingankar, G. Wen, R. M. Salem, M. Das, et al. Naturally Occurring Human Genetic Variation in the 3'-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent Fashion J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1468 - 1481. [Abstract] [Full Text] [PDF]

				D. Fairweather, S. Frisancho-Kiss, and N. R. Rose Sex Differences in Autoimmune Disease from a Pathological Perspective Am. J. Pathol., September 1, 2008; 173(3): 600 - 609. [Abstract] [Full Text] [PDF]

				T. Henriques, X. Zhang, F. B. Yiannikouris, A. Daugherty, and L. A. Cassis Androgen Increases AT1a Receptor Expression in Abdominal Aortas to Promote Angiotensin II-Induced AAAs in Apolipoprotein E-Deficient Mice Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1251 - 1256. [Abstract] [Full Text] [PDF]

				J. H. Page, J. Ma, K. M. Rexrode, N. Rifai, J. E. Manson, and S. E. Hankinson Plasma Dehydroepiandrosterone and Risk of Myocardial Infarction in Women Clin. Chem., July 1, 2008; 54(7): 1190 - 1196. [Abstract] [Full Text] [PDF]

				S. A. Hall, A. B. Araujo, G. R. Esche, R. E. Williams, R. V. Clark, T. G. Travison, and J. B. McKinlay Treatment of Symptomatic Androgen Deficiency: Results From the Boston Area Community Health Survey Arch Intern Med, May 26, 2008; 168(10): 1070 - 1076. [Abstract] [Full Text] [PDF]

				M. Grossmann, M. C. Thomas, S. Panagiotopoulos, K. Sharpe, R. J. MacIsaac, S. Clarke, J. D. Zajac, and G. Jerums Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1834 - 1840. [Abstract] [Full Text] [PDF]

				L. M. Montano, E. Calixto, A. Figueroa, E. Flores-Soto, V. Carbajal, and M. Perusquia Relaxation of Androgens on Rat Thoracic Aorta: Testosterone Concentration Dependent Agonist/Antagonist L-Type Ca2+ Channel Activity, and 5{beta}-Dihydrotestosterone Restricted to L-Type Ca2+ Channel Blockade Endocrinology, May 1, 2008; 149(5): 2517 - 2526. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, S. Livadas, S. A Kandarakis, A. Margeli, and I. Papassotiriou Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism? Eur. J. Endocrinol., April 1, 2008; 158(4): 525 - 531. [Abstract] [Full Text] [PDF]

				A. Martorell, J. Blanco-Rivero, R. Aras-Lopez, A. Sagredo, G. Balfagon, and M. Ferrer Orchidectomy increases the formation of prostanoids and modulates their role in the acetylcholine-induced relaxation in the rat aorta Cardiovasc Res, February 1, 2008; 77(3): 590 - 599. [Abstract] [Full Text] [PDF]

				L. J. Gooren, E. J. Giltay, and M. C. Bunck Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 19 - 25. [Abstract] [Full Text] [PDF]

				K.-T. Khaw, M. Dowsett, E. Folkerd, S. Bingham, N. Wareham, R. Luben, A. Welch, and N. Day Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study Circulation, December 4, 2007; 116(23): 2694 - 2701. [Abstract] [Full Text] [PDF]

				F. L. Rocha, E. C. Carmo, F. R. Roque, N. Y. Hashimoto, L. V. Rossoni, C. Frimm, I. Aneas, C. E. Negrao, J. E. Krieger, and E. M. Oliveira Anabolic steroids induce cardiac renin-angiotensin system and impair the beneficial effects of aerobic training in rats Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3575 - H3583. [Abstract] [Full Text] [PDF]

				A. Tivesten, D. Mellstrom, H. Jutberger, B. Fagerberg, B. Lernfelt, E. Orwoll, M. K. Karlsson, O. Ljunggren, and C. Ohlsson Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Arterial Disease in Elderly Men: The MrOS Study in Sweden J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1070 - 1076. [Abstract] [Full Text] [PDF]

				P. Crabbe, V. Bogaert, D. De Bacquer, S. Goemaere, H. Zmierczak, and J. M. Kaufman Part of the Interindividual Variation in Serum Testosterone Levels in Healthy Men Reflects Differences in Androgen Sensitivity and Feedback Set Point: Contribution of the Androgen Receptor Polyglutamine Tract Polymorphism J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3604 - 3610. [Abstract] [Full Text] [PDF]

				P. Y. Liu, J. Beilin, C. Meier, T. V. Nguyen, J. R. Center, P. J. Leedman, M. J. Seibel, J. A. Eisman, and D. J. Handelsman Age-Related Changes in Serum Testosterone and Sex Hormone Binding Globulin in Australian Men: Longitudinal Analyses of Two Geographically Separate Regional Cohorts J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3599 - 3603. [Abstract] [Full Text] [PDF]

				J. Bourghardt, G. Bergstrom, A. Krettek, S. Sjoberg, J. Boren, and A. Tivesten The Endogenous Estradiol Metabolite 2-Methoxyestradiol Reduces Atherosclerotic Lesion Formation in Female Apolipoprotein E-Deficient Mice Endocrinology, September 1, 2007; 148(9): 4128 - 4132. [Abstract] [Full Text] [PDF]

				S. A. Hall, S. T. Page, T. G. Travison, R. B. Montgomery, C. L. Link, and J. B. McKinlay Do Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1587 - 1594. [Abstract] [Full Text] [PDF]

				S. Rohrmann, W. G. Nelson, N. Rifai, T. R. Brown, A. Dobs, N. Kanarek, J. D. Yager, and E. A. Platz Serum Estrogen, But Not Testosterone, Levels Differ between Black and White Men in a Nationally Representative Sample of Americans J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2519 - 2525. [Abstract] [Full Text] [PDF]

				H. Kohno, N. Takahashi, T. Shinohara, T. Ooie, K. Yufu, M. Nakagawa, H. Yonemochi, M. Hara, T. Saikawa, and H. Yoshimatsu Receptor-Mediated Suppression of Cardiac Heat-Shock Protein 72 Expression by Testosterone in Male Rat Heart Endocrinology, July 1, 2007; 148(7): 3148 - 3155. [Abstract] [Full Text] [PDF]

				R. J. Roman and J. H. Lombard Does 20-Hydroxyeicosatetraenoic Acid Contribute to Sex Differences in Cardiovascular Risk by Increasing Oxidative Stress? Hypertension, July 1, 2007; 50(1): 37 - 38. [Full Text] [PDF]

				H. Singh, J. Cheng, H. Deng, R. Kemp, T. Ishizuka, A. Nasjletti, and M. L. Schwartzman Vascular Cytochrome P450 4A Expression and 20-Hydroxyeicosatetraenoic Acid Synthesis Contribute to Endothelial Dysfunction in Androgen-Induced Hypertension Hypertension, July 1, 2007; 50(1): 123 - 129. [Abstract] [Full Text] [PDF]

				A. B. Araujo, V. Kupelian, S. T. Page, D. J. Handelsman, W. J. Bremner, and J. B. McKinlay Sex Steroids and All-Cause and Cause-Specific Mortality in Men Arch Intern Med, June 25, 2007; 167(12): 1252 - 1260. [Abstract] [Full Text] [PDF]

				M.-J. Chen, W.-S. Yang, J.-H. Yang, C.-L. Chen, H.-N. Ho, and Y.-S. Yang Relationship Between Androgen Levels and Blood Pressure in Young Women With Polycystic Ovary Syndrome Hypertension, June 1, 2007; 49(6): 1442 - 1447. [Abstract] [Full Text] [PDF]

				S. Bhasin, R. A. Parker, F. Sattler, R. Haubrich, B. Alston, T. Umbleja, C. M. Shikuma, and for the AIDS Clinical Trials Group Protocol A5079 Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1049 - 1057. [Abstract] [Full Text] [PDF]

				A. D'Andrea, P. Caso, G. Salerno, R. Scarafile, G. De Corato, C. Mita, G. Di Salvo, S. Severino, S. Cuomo, B. Liccardo, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis * COMMENTARY Br. J. Sports Med., March 1, 2007; 41(3): 149 - 155. [Abstract] [Full Text] [PDF]

				C. F. Deschepper and B. Llamas Hypertensive Cardiac Remodeling in Males and Females: From the Bench to the Bedside Hypertension, March 1, 2007; 49(3): 401 - 407. [Full Text] [PDF]

				J. Blanco-Rivero, A. Sagredo, G. Balfagon, and M. Ferrer Protein kinase C activation increases endothelial nitric oxide release in mesenteric arteries from orchidectomized rats J. Endocrinol., January 1, 2007; 192(1): 189 - 197. [Abstract] [Full Text] [PDF]

				C. Foresta, N. Caretta, A. Lana, L. De Toni, A. Biagioli, A. Ferlin, and A. Garolla Reduced Number of Circulating Endothelial Progenitor Cells in Hypogonadal Men J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4599 - 4602. [Abstract] [Full Text] [PDF]

				A. Tivesten, J. Hulthe, K. Wallenfeldt, J. Wikstrand, C. Ohlsson, and B. Fagerberg Circulating Estradiol Is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4433 - 4437. [Abstract] [Full Text] [PDF]

				J. Blanco-Rivero, A. Sagredo, G. Balfagon, and M. Ferrer Orchidectomy increases expression and activity of Cu/Zn-superoxide dismutase, while decreasing endothelial nitric oxide bioavailability. J. Endocrinol., September 1, 2006; 190(3): 771 - 778. [Abstract] [Full Text] [PDF]

				J. Arnlov, M. J. Pencina, S. Amin, B.-H. Nam, E. J. Benjamin, J. M. Murabito, T. J. Wang, P. E. Knapp, R. B. D'Agostino Sr., S. Bhasin, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med, August 1, 2006; 145(3): 176 - 184. [Abstract] [Full Text] [PDF]

				A Tivesten, E Bollano, H C Nystrom, C Alexanderson, G Bergstrom, and A Holmang Cardiac concentric remodelling induced by non-aromatizable (dihydro-)testosterone is antagonized by oestradiol in ovariectomized rats. J. Endocrinol., June 1, 2006; 189(3): 485 - 491. [Abstract] [Full Text] [PDF]

				G. Bernini, D. Versari, A. Moretti, A. Virdis, L. Ghiadoni, M. Bardini, C. Taurino, D. Canale, S. Taddei, and A. Salvetti Vascular Reactivity in Congenital Hypogonadal Men before and after Testosterone Replacement Therapy J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1691 - 1697. [Abstract] [Full Text] [PDF]

				D. J. Handelsman and P. Y. Liu Klinefelter's Syndrome--A Microcosm of Male Reproductive Health. J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1220 - 1222. [Full Text] [PDF]

				K. J. Milne, D. B. Thorp, C. W. J. Melling, and E. G. Noble Castration inhibits exercise-induced accumulation of Hsp70 in male rodent hearts Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1610 - H1616. [Abstract] [Full Text] [PDF]

				M. Jayachandran and V. M. Miller Mechanisms of estrogenic vascular protection Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H507 - H508. [Full Text] [PDF]

				R. G. Mishra, F. Z. Stanczyk, K. A. Burry, S. Oparil, B. S. Katzenellenbogen, M. L. Nealen, J. A. Katzenellenbogen, and R. K. Hermsmeyer Metabolite ligands of estrogen receptor-{beta} reduce primate coronary hyperreactivity Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H295 - H303. [Abstract] [Full Text] [PDF]

				I. M. Thompson, C. M. Tangen, P. J. Goodman, J. L. Probstfield, C. M. Moinpour, and C. A. Coltman Erectile Dysfunction and Subsequent Cardiovascular Disease JAMA, December 21, 2005; 294(23): 2996 - 3002. [Abstract] [Full Text] [PDF]

				A. Razmara, D. N. Krause, and S. P. Duckles Testosterone augments endotoxin-mediated cerebrovascular inflammation in male rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1843 - H1850. [Abstract] [Full Text] [PDF]

				J. M. Kaufman and A. Vermeulen The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications Endocr. Rev., October 1, 2005; 26(6): 833 - 876. [Abstract] [Full Text] [PDF]

				L. P. Mayer, C. A. Dyer, R. L. Eastgard, P. B. Hoyer, and C. L. Banka Atherosclerotic Lesion Development in a Novel Ovary-Intact Mouse Model of Perimenopause Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1910 - 1916. [Abstract] [Full Text] [PDF]

				M. Perusquia, E. Navarrete, J. Jasso-Kamel, and L. M. Montano Androgens Induce Relaxation of Contractile Activity in Pregnant Human Myometrium at Term: A Nongenomic Action on L-Type Calcium Channels Biol Reprod, August 1, 2005; 73(2): 214 - 221. [Abstract] [Full Text] [PDF]

				R. J. Gonzales, A. A. Ghaffari, S. P. Duckles, and D. N. Krause Testosterone treatment increases thromboxane function in rat cerebral arteries Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H578 - H585. [Abstract] [Full Text] [PDF]

				M. Hersberger, J. Muntwyler, H. Funke, J. Marti-Jaun, H. Schulte, G. Assmann, T. F. Luscher, and A. von Eckardstein The CAG Repeat Polymorphism in the Androgen Receptor Gene Is Associated with HDL-Cholesterol but Not with Coronary Atherosclerosis or Myocardial Infarction Clin. Chem., July 1, 2005; 51(7): 1110 - 1115. [Abstract] [Full Text] [PDF]

				M. E. Mendelsohn and R. H. Karas Molecular and Cellular Basis of Cardiovascular Gender Differences Science, June 10, 2005; 308(5728): 1583 - 1587. [Abstract] [Full Text] [PDF]

				A. Aviv, J. Shay, K. Christensen, and W. Wright The Longevity Gender Gap: Are Telomeres the Explanation? Sci. Aging Knowl. Environ., June 8, 2005; 2005(23): pe16 - pe16. [Abstract] [Full Text]

				R. G. Mishra, R. K. Hermsmeyer, K. Miyagawa, P. Sarrel, B. Uchida, F. Z. Stanczyk, K. A. Burry, D. R. Illingworth, and F. J. Nordt Medroxyprogesterone Acetate and Dihydrotestosterone Induce Coronary Hyperreactivity in Intact Male Rhesus Monkeys J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3706 - 3714. [Abstract] [Full Text] [PDF]

				A. Xu, K. W. Chan, R. L. C. Hoo, Y. Wang, K. C. B. Tan, J. Zhang, B. Chen, M. C. Lam, C. Tse, G. J. S. Cooper, et al. Testosterone Selectively Reduces the High Molecular Weight Form of Adiponectin by Inhibiting Its Secretion from Adipocytes J. Biol. Chem., May 6, 2005; 280(18): 18073 - 18080. [Abstract] [Full Text] [PDF]

				A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746. [Abstract] [Full Text] [PDF]

				E. Estebanez-Perpina, J. M. R. Moore, E. Mar, E. Delgado-Rodrigues, P. Nguyen, J. D. Baxter, B. M. Buehrer, P. Webb, R. J. Fletterick, and R. K. Guy The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor J. Biol. Chem., March 4, 2005; 280(9): 8060 - 8068. [Abstract] [Full Text] [PDF]

				I. S. Brum, P. M. Spritzer, F. Paris, M. A. Maturana, F. Audran, and C. Sultan Association Between Androgen Receptor Gene CAG Repeat Polymorphism and Plasma Testosterone Levels in Postmenopausal Women Reproductive Sciences, February 1, 2005; 12(2): 135 - 141. [Abstract] [PDF]

				P. Y. Liu, R. C. Christian, M. Ruan, V. M. Miller, and L. A. Fitzpatrick Correlating Androgen and Estrogen Steroid Receptor Expression with Coronary Calcification and Atherosclerosis in Men without Known Coronary Artery Disease J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1041 - 1046. [Abstract] [Full Text] [PDF]

				J. F. Reckelhoff Sex Steroids, Cardiovascular Disease, and Hypertension: Unanswered Questions and Some Speculations Hypertension, February 1, 2005; 45(2): 170 - 174. [Full Text] [PDF]

				D. K. Bowles, K. K. Maddali, V. K. Ganjam, L. J. Rubin, D. L. Tharp, J. R. Turk, and C. L. Heaps Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2091 - H2098. [Abstract] [Full Text] [PDF]

				P. Y. Liu, R. S. Swerdloff, and J. D. Veldhuis The Rationale, Efficacy and Safety of Androgen Therapy in Older Men: Future Research and Current Practice Recommendations J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4789 - 4796. [Abstract] [Full Text] [PDF]

				Y.-L. Gui, C.-H. He, J. K. Amory, W. J. Bremner, E-X. Zheng, J. Yang, P.-J. Yang, and E.-S. Gao Male Hormonal Contraception: Suppression of Spermatogenesis by Injectable Testosterone Undecanoate Alone or With Levonorgestrel Implants in Chinese Men J Androl, September 1, 2004; 25(5): 720 - 727. [Abstract] [Full Text] [PDF]

				D. J. Handelsman Designer Androgens in Sport: When Too Much Is Never Enough Sci. Signal., August 3, 2004; 2004(244): pe41 - pe41. [Abstract] [Full Text] [PDF]

				T. A. Henriques, J. Huang, S. S. D'Souza, A. Daugherty, and L. A. Cassis Orchidectomy, But Not Ovariectomy, Regulates Angiotensin II-Induced Vascular Diseases in Apolipoprotein E-Deficient Mice Endocrinology, August 1, 2004; 145(8): 3866 - 3872. [Abstract] [Full Text] [PDF]

				V. M. Miller, D. J. Tindall, and P. Y. Liu Of Mice, Men, and Hormones Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 995 - 997. [Full Text] [PDF]

				J R Payne, P J Kotwinski, and H E Montgomery Cardiac effects of anabolic steroids Heart, May 1, 2004; 90(5): 473 - 475. [Abstract] [Full Text] [PDF]

				A. K. Death, K. C. Y. McGrath, M. A. Sader, S. Nakhla, W. Jessup, D. J. Handelsman, and D. S. Celermajer Dihydrotestosterone Promotes Vascular Cell Adhesion Molecule-1 Expression in Male Human Endothelial Cells via a Nuclear Factor-{kappa}B-Dependent Pathway Endocrinology, April 1, 2004; 145(4): 1889 - 1897. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, P. Y. Articles by Handelsman, D. J. Search for Related Content PubMed PubMed Citation Articles by Liu, P. Y. Articles by Handelsman, D. J.